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Pancreatic ductal adenocarcinoma (PDAC) is a highly heterogeneous disease 
which is significantly driven by epigenetic alterations, e.g. installed by 
overexpression of Enhancer of Zeste homologue 2 (EZH2). EZH2 constitutes 
the catalytic member of the PRC2 complex and plays a pivotal role in gene 
repression by mediating histone methylation (H3K27me3). High EZH2 
expression levels are predominantly found in undifferentiated PDAC tumors 
and are associated with poor prognosis. However, the underlying mechanisms 
that bridge EZH2 activity to PDAC dedifferentiation remain elusive. Here we 
aim to dissect the mechanistic and functional role of EZH2 in PDAC 
progression and dedifferentiation. 
The functional implications of EZH2 are investigated in vitro in primary PDAC 
cells upon genetic (CRISPR/Cas9 and shRNA-based) or pharmacological 
inhibition (EPZ6438) of EZH2 and in vivo utilizing transgenic mice of EZH2 
deficiency and Patient-Derived-Xenograft (PDX) models. EZH2-dependent 
gene signatures are identified based on ChIP-and RNA-seq analyses and are 
further validated by independent gene expression studies.  
EZH2 activity correlates with increased tumor incidence and metastatic 
propensity in murine PDAC and drives dedifferentiation in human PDAC. 
Blockade of the histone methyltransferase reduces proliferation, invasion and 
stemness features in PDAC cells. Accordingly, genome wide binding- and 
expression analyses reveal EZH2 as a repressor of differentiation-associated 
gene signatures and indicate that blockage of EZH2 activity induces a gene 
signature shift towards classical and less aggressive molecular PDAC 
subtypes. The endodermal transcription factor encoding GATA6 gene is 
identified as one of the most significantly regulated direct EZH2 targets. 
Consequently, abrogation of GATA6 upregulation in the context of EZH2-
deficiency partially counteracts the acquisition of classical gene signatures and 
reinstalls their invasive capacities of PDAC cells, suggesting that the 





Together, our findings link the EZH2-GATA6 axis to PDAC subtype identity and 
suggest EZH2 inhibition as a promising therapeutic strategy to induce subtype-






 Pancreatic cancer 
The pancreas is a glandular organ that lies behind the lower part of the 
stomach in the abdomen. It mainly consists of two functional units - endocrine 
and exocrine. The endocrine cells help regulate the blood glucose levels, and 
the exocrine unit, which is made of acinar and ductal cells, produces and 
releases digestive enzymes (Zhou and Melton 2018). The tumor can form in 
cells from any of these compartments but 90 % of the pancreatic cancers are 
pancreatic ductal adenocarcinoma (PDAC), which arise from the acinar cells of 
the pancreas (Iguchi et al. 2016).  
 Pancreatic cancer statistics 
Pancreatic cancer is currently the third leading cause of cancer-related deaths 
in the United States (Tavakkoli et al. 2020) and fourth in Europe (Ferlay et al. 
2018). With the records of increasing incidence, consistently low survival rates 
and no significant improvements in mortality trends, it is projected to be the 
second leading cause of cancer-related deaths by 2030 (Tavakkoli et al. 2020). 
According to GLOBOCAN 2018 estimates, pancreatic cancer is the 11th most 
common cancer in the world and was reported to cause 432,242 deaths (4.5 % 
of all deaths caused by cancer) in 2018 (Bray et al. 2018). With the highest 
mortality rate of 91 %, to date, it remains one of the deadliest gastrointestinal 
malignancies worldwide. Even though the overall incidence of pancreatic 
cancer is relatively less, the incidence almost equals the mortality rate (Gordon-
Dseagu et al. 2018; Rahib et al. 2014). Despite all the scientific efforts in the 
last few decades, the five-year survival rate of PDAC remains at 9 %, which is 
the lowest of all cancer entities (Rawla, Sunkara, and Gaduputi 2019). These 
alarming statistics are reasoned by late diagnosis due to lack of specific early 
detection methods and no predictive symptoms or nonspecific symptoms. 
Furthermore, tumors are unresectable when detected at an advanced stage. 
PDAC displays a high recurrence rate after surgery and an intrinsic resistance 
against diverse therapeutic regimens, mainly because of untailored therapeutic 
strategies, extensive tumor heterogeneity and dynamic cellular plasticity (Orth 




and additionally upon failure of chemotherapy, they develop accelerated tumor 
growth, resistance and metastasis (Juiz, Iovanna, and Dusetti 2019). 
Consequently, advanced research is urgently needed for the better 
understanding of disease etiology and the development of novel therapeutic 
strategies.  
 Pancreatic carcinogenesis 
The origin of PDAC was deciphered in the 21st century with the development of 
genetically engineered mouse models (GEMMs) of PDAC. For a long time, 
PDAC was thought to originate from the ductal cells of the pancreas (J. M. 
Bailey, DelGiorno, and Crawford 2014; Busnardo et al. 1983). Later, it was 
experimentally confirmed that PDAC originates from the acinar cells, which are 
known to possess a high degree of cellular plasticity (J. M. Bailey et al. 2015; 
Kopp et al. 2012; Ray et al. 2011). In 1988, Smit et al. set a link between a 
mutation in codon 12 in KRAS and PDAC (Smit et al. 1988). Subsequently, 
many GEMMs verified the association and confirmed that point mutations in the 
KRAS gene is the earliest event for the onset of PDAC (Hingorani et al. 2003; 
Olive and Tuveson 2006). The KRAS gene codes for the KRAS protein, a 
Guanosine triphisphatase (GTPase), which acts as a switch to regulate the 
RAS/MAPK signaling pathway. The mutation results in a constitutively active 
KRAS protein that continuously drives proliferation independent of external 
stimuli (Ellis and Clark 2000). The  KRAS oncogene is found to be mutated in 
90 % of PDACs (Hansel, Kern, and Hruban 2003; Hruban et al. 1993), and this 
gatekeeper KRAS mutation is vital for the initiation of PDAC (Kandha et al. 
2012). Studies in mouse models show that upon acinar damage, mutant KRAS 
blocks acinar regeneration, thus resulting in progression of Acinar-to-ductal 
metaplasia (ADM) to Pancreatic Intraepithelial Neoplasia (PanIN) formation 
(Morris et al. 2010). PanINs represent PDAC precursor lesions, which progress 
through three well-defined stages (PanIN1A/1B, PanIN2, PanIN3) and have the 
potential to cause PDAC. These lesions differ in their level of cytological 
abnormalities (Guerra et al. 2007) and are associated with specific step-wise 
genetic changes. Oncogenic KRAS is present in 90 % of PanIN1A/1B, 
CDKN2A is found to be inactivated in 90 % of PanIN2 (Caldas et al. 1994; 




Berrozpe et al. 1994; Rozenblum et al. 1997; Solcia, Bonato, and Ranzani 
1994) and loss of SMAD4 is seen in 55 % (Hahn et al. 1996) of PanIN3 (Guerra 
et al. 2007; Iacobuzio-Donahue 2012; Thilo Welsch, Jorg Kleeff, and Helmut 
Friess 2007).  
Although oncogenic activation of KRAS is a very early initiating event for PDAC 
origin, certain environmental stimuli like stress or acinar cell injury accelerate 
PDAC initiation and further progression (Dumartin et al. 2017). Accordingly, 
chronic pancreatitis displays a crucial risk factor for PDAC development (Yadav 
and Lowenfels 2013). These events ultimately enhance the secretion of 
inflammatory factors which in combination with mutant KRAS boost progression 
of PDAC (Baer et al. 2014; Ye et al. 2019; Young et al. 2019).   
 PDAC heterogeneity 
 Molecular heterogeneity of PDAC 
One of the major reasons for the aggressive tumor biology and the therapeutic 
resistance of PDAC is its high molecular heterogeneity. Next-generation 
sequencing approaches conducted in the last few years have significantly 
extended our understanding of the molecular complexity of PDAC. The first 
whole-exome sequencing experiment in pancreatic cancer specimens 
conducted in 2008 identified alterations in a number of oncogenes and tumor 
suppressor genes (Jones et al. 2008). Further, numerous follow-up studies 
have revealed huge amount of information regarding the wide spectrum of 
mutational and copy number variations in PDAC (Adamo et al. 2017; P. Bailey 
et al. 2016). These reports have not only reaffirmed signature mutations in 
KRAS, CDKN2A, SMAD4 and TP53 genes but revealed additional genetic 
alterations that occur throughout the process of tumor progression, although at 
lower prevalence (P. Bailey et al. 2016; Biankin et al. 2012; Du et al. 2017). 
However, recent work indicates that phenotypic features of PDAC are not only 
driven by genetic alterations but are significantly determined by epigenetic 
changes (G. Lomberk et al. 2018; Nicolle et al. 2017). Hence, epigenetic 







Figure 1: Schematic depicting heterogeneity in pancreatic cancer. 
Genetic and molecular heterogeneity exists between different patients (intertumoral 
heterogeneity), primary and metastatic sites within the same patient as well as within 
different parts of the same tumor (intratumoral heterogeneity). 
 
 Molecular PDAC subtypes 
The high degree of molecular heterogeneity in PDAC is reflected by the 
identification of various molecular PDAC subtypes with prognostic and therapy 
predictive relevance (Aung et al. 2019; P. Bailey et al. 2016; Collisson et al. 
2011; Moffitt et al. 2015). The first study aiming at molecular PDAC subtyping 
was performed by Collisson et al. in 2011 and is based on microarray-based 
transcriptome analysis in microdissected primary resected PDAC samples as 
well as in mouse and human cell lines. The authors unraveled three subtypes: 
classical (increased expression of epithelial genes), QM (quasi-mesenchymal, 
increased expression of mesenchymal genes) and exocrine (increased 
expression of digestive enzymes genes). They also show the association of 
these subtypes with clinical outcome and differences in response to therapy. 
They developed PDAssigner gene sets comprising 62 genes that define their 
subtypes. (Collisson et al. 2011). Following this up, in 2014, Kim et al. 




and shared similar findings. They found three molecular subtypes: subtype1 
(similar to classical subtype with enriched immune pathways), subtype2 
(resembles QM PDA) and subtype3 (similar to exocrine-like) which had a 
significant correlation with tumor size, metastasis and survival (S. Kim et al. 
2014). 
In 2015, Moffit et al. performed virtual microdissection to separate stroma from 
epithelial tumors and looked for gene expression in both tumoral and stromal 
compartment. They conducted microarray analysis in both primary and 
metastatic samples and further validated their results by RNA-sequencing 
(RNA-seq), which is a more sensitive method and can capture a broader range 
(Rodríguez-García, Sola-Landa, and Barreiro 2017). They presented two 
subtypes for the tumor compartment: classical and basal-like which overlapped 
with the Collisson classical and QM subtypes, respectively. The authors also 
distinguished two stromal subtypes: Normal and activated stroma which 
independently serve as prognostic markers (Moffitt et al. 2015). Soon after this, 
in 2016, Janky et al. published their microarray data in resected samples, 
where they found three clusters largely reflecting the findings from Collisson et 
al (Janky et al. 2016). In 2016, Bailey et al. in collaboration with International 
Cancer Genome Consortium (ICGC), performed integrated genomic analysis 
and gene expression analysis using deep-exome sequencing and RNA-seq 
approaches. They explored 32 significantly mutated genes that aggregated into 
10 molecular pathways. Clustering from the gene expression analysis revealed 
four clinically relevant subtypes: Progenitor, Aberrantly differentiated endocrine 
exocrine (ADEX), Squamous and Immunogenic. The progenitor and squamous 
subtypes shared common features with Collisson’s classical and QM subtypes, 
respectively (P. Bailey et al. 2016). However, work from The Cancer Genome 
Atlas (TCGA) categorized ADEX and Immunogenic subtypes as less pure. 
Using the transcriptomic data from Bailey et al., Müller classified five different 
clusters: cluster1 overlapped with squamous subtype, cluster2 had more 
epithelial cell signatures, cluster3 had signatures related to EMT and MAPK 
pathways which are characteristics of undifferentiated tumors, cluster4 was 
similar to the immunogenic subtype and cluster5 resembled ADEX subtype 




More recently, Puleo et al. conducted a large investigation of the transcriptional 
landscape by performing microarray analysis in 309 paraffin-embedded 
samples. The study integrates data from epithelial and stromal compartments. 
The unsupervised classification of the whole tumor entity revealed five 
subtypes: Pure classical, immune classical, desmoplastic, stroma activated and 
pure-basal-like. The high tumor cellularity classification revealed two well-
defined subtypes: classical and basal-like. This study captured the molecular 
diversification of PDAC compartments and validated the existence of classical 
and basal subtypes as described in all previous PDAC stratification studies 
(Puleo et al. 2018). In the follow-up study, Maurer et al. (2019) carried out RNA-
sequencing in 60 resected samples and revealed two epithelial (classical and 
basal-like) and two stromal (ECM rich and immune rich) subtypes (Maurer et al. 
2019). 
In summary, two subtypes exist in the epithelial PDAC compartment, which 
have been univocally identified by all transcription-based subtyping studies 
conducted in PDAC so far: classical and basal-like. The classical molecular 
PDAC subtype is characterized by the expression of epithelial differentiation-
related gene signatures, is less aggressive and displays a relatively good 
prognosis. In contrast, basal-like PDAC is highly aggressive and is associated 
with chemoresistance and low survival (P. Bailey et al. 2016; Collisson et al. 
2011; G. Lomberk et al. 2018; Moffitt et al. 2015; Puleo et al. 2018). Hence, the 
aforementioned subtyping studies have not only allowed for a better 
understanding of the remarkable molecular heterogeneity of PDAC, but have 
revealed molecular explanations for the poor efficacy of “one-size-fits-all” 
therapeutic approaches in PDAC treatment. Moreover, these studies clearly 
emphasize the necessity of considering the diverse molecular PDAC 
characteristics for pursuing tailored therapeutic strategies to combat pancreatic 
cancer. Finally, the aforementioned studies indicate that molecular PDAC 
subtypes are primarily defined at the level of gene transcription. Hence, a 
thorough understanding of the mechanistic regulation of PDAC subtypes 
requires the exploration of epigenetic alterations underlying the classification of 






Epigenetics literally translates to ‘outside genetics’. The term epigenetics is 
used to describe the heritable changes in gene expression and phenotype 
without any alterations in the DNA sequence itself (Holliday 1994). 
Epigenomics means the genome-wide analysis of the epigenetic process 
(Ideraabdullah and Zeisel 2018). Epigenetics can be broadly classified into 
three principle mechanisms (Bishop and Ferguson 2015; Virani et al. 2012): 
1. Chromatin regulatory processes  
2. DNA Methylation 
3. Non-coding RNA  
In each eukaryotic cell, the DNA strand is around 2 meters in length. To fit itself 
into a small nucleus of some 6 µm diameter, the DNA coils around nuclear 
proteins called histones and forms a compact structure called chromatin (Hauer 
and Gasser 2017). In this process, the DNA becomes inaccessible for DNA 
binding factors and hence does not get transcribed. This state of chromatin 
which displays a high degree of compaction is defined as heterochromatin. For 
gene transcription, the chromatin structure needs to shift from a condensed to a 
transcriptionally accessible relaxed state. This relaxed chromatin state which 
enables active transcription is termed as euchromatin (Corradini et al. 2007; 
Fedorova and Zink 2008). The dynamic reorganization of the chromatin 
architecture and hence the regulation of gene transcription are controlled by 
two major processes: Chromatin remodeling and histone modification. 
Given the critical involvement of chromatin regulatory processes in controlling 
gene transcription, alterations of chromatin-associated processes contribute to 
several pathophysiological conditions, including cancer (Bauer and Martin 
2017; Morgan and Shilatifard 2015). For example, mutation of chromatin 
regulatory proteins or their altered activity have a severe impact on cellular 
functions that support the development and progression of cancer (Jian Chen 
et al. 2016). Accordingly, in PDAC approximately 38 % of specimens carry 
mutational events in chromatin regulatory proteins (P. Bailey et al. 2016), which 
can have prognostic implications (Grassi et al. 2018). Moreover, several 
genetic alterations in PDAC and subsequent dysregulation in signaling 




regulatory proteins with potential impact on the chromatin landscape (Liu et al. 
2016). 
The following paragraphs summarize the major physiological mechanisms 
controlling chromatin remodeling and histone modifications and provide 
examples, how alterations of chromatin regulatory protein functions can 
contribute to PDAC development and progression.  
 Nucleosome remodeling  
The nucleosome is the fundamental unit of chromatin. Each nucleosome is a 
DNA-protein complex, which comprises 146 bp of DNA wrapped around a 
histone octamer (2 sets of histone H2A, H2B, H3, and H4) (Van Holde et al. 
1980). Nucleosome remodeling is mediated by large multiprotein complexes 
that contain several subunits, including the Adenosine triphosphatase (ATPase) 
catalytic subunit. The energy released by the hydrolysis of ATP is utilized to 
slide nucleosome along the DNA, thereby exposing the DNA to transcription 
factors (Tyagi et al. 2016). Currently, four families of remodeling complexes are 
known: SWI/SNF, ISWI, CHD and INO80, (Musladin et al. 2014) each with 
distinct biological functions. All complexes have a conserved ATPase subunit 
and other members are responsible for the complexes’ recruitment to DNA or 
regulate the ATPase activity (Mani et al. 2017). 
The subunits of the complexes are known to be inactivated in many human 
cancers and are hence referred to as tumor suppressors. Importantly, 
according to investigations by Bailey et al., mutations in components of the 
SWI/SNF complex were detected in 14 % of PDAC samples (P. Bailey et al. 
2016). Importantly, inactivation of selective SWI/SNF complex members has 
been associated with poor survival in PDAC patients (Yoon et al. 2019) and 
impact on the senstitivity towards platinum-based therapy regimens (Hasan and 
Ahuja 2019), hence emphasizing the prognostic and predictive relevance of 





 Histone modifications 
Histone tails are susceptible to post-translational modifications, generally 
referred to as ‘histone marks’. The type of histone mark and its relative location 
on the gene (Transcription start site (TSS), promoters, gene body) determines if 
the gene is expressed or repressed. The enzymes that mark the histones are 
referred to as writers, readers or erasers, which add, recognize or remove the 
mark, respectively (Janzen et al. 2010). The consequences of distinct histone 
modifications on DNA accessibility and transcriptional activity are determined 
by the type (e.g. acetylation, methylation, phosphorylation, ubiquitination and 
SUMOylation) and the localization (histone protein and amino acid residue) of 
the histone modification (Audia and Campbell 2016; Goll and Bestor 2002). 
 
Figure 2: Schematics depicting the chromatin regulators. 
Three main categories of chromatin regulators responsible for post-translational 
modifications (PTMs) include writers (adds the modification), readers (recognizes 
particular histone marks) and erasers (catalyze the removal of histone modification). 
 
 
1.3.2.1 Histone acetylation 
In the nucleosome, negatively charged DNA and the positively charged 
histones form the DNA-protein complex (Tammen, Friso, and Choi 2013). 
Histone acetylation (also known as lysine acetylation) is the process of adding 
acetyl groups onto histone tail residues. This neutralizes the positive charge on 
the amino acid residue, thereby loosening DNA-histone contact resulting in an 
open chromatin structure that enables gene transcription (Sterner and Berger 
2000). On the contrary, histone deacetylation, where acetyl groups are erased, 




(De Ruijter et al. 2003). The addition and removal of acetyl groups on lysine 
residues are mediated by histone acetyltransferases (HATs) and Histone 
deacetylases (HDACs), respectively (Singh, Reindl, and Jansen 2019). Further, 
acetylated marks serve as docking sites where chromatin reader proteins bind 
(Yun et al. 2011). 
Aberrant activity of HATs, HDACs and acetylation readers are correlated with 
PDAC development and progression (Glozak and Seto 2007; Köenig et al. 
2010; Ouaïssi et al. 2014; Stenzinger et al. 2013). Considering the implications 
of aberrant acetylation in cancer, several inhibitors are being developed against 
histone lysine writers (Kunnumakkara et al. 2007; Sahu, Batra, and Srivastava 
2009), readers (Pérez-Salvia and Esteller 2017; Y. Xu and Vakoc 2017) and 
erasers (Marmorstein and Zhou 2014; Mottamal et al. 2015). 
1.3.2.2  Histone methylation 
Histone methylation is the process where methyl groups are added to 
lysine/arginine residues of histones (Hyun et al. 2017). Unlike acetylation which 
is always associated with gene activation, methylation can be correlated to 
either gene expression or repression depending on which lysine/arginine 
residue is methylated and how many methyl groups are added (mono-, di- or 
trimethylation) (Dambacher, Hahn, and Schotta 2010). For instance, 
trimethylation of lysine 4 on histone H3 (H3K4me3) by the trithorax complex 
induces gene expression whereas H3K27me3 installed by members of the 
Polycomb repressor complex 2 (PRC2) induces gene repression 
(Schuettengruber et al. 2007). Histone methyltransferases (HMTs) which 
methylate lysine and arginine residues on histones are referred to as lysine 
methyltransferases (KMTs) and protein arginine methyltransferases (PRMTs), 
respectively. (Lorenzo and Bedford 2011; Upadhyay and Cheng 2011). Around 
50 KMTs are known so far, where all of them (except Dot1) have a conserved 
Su(var)3-9,EZH2 and Trithorax (SET) domain, which is responsible for the 
methyltransferase activity (G. A. Lomberk, Iovanna, and Urrutia 2016). Lysine 
demethylases (KDMs) counteracts KMT activity by mediating the removal of 
methyl marks (Thinnes et al. 2014).  
Many histone- methylases and demethylases are known to be mutated, 




Reindl, and Jansen 2019). For instance, studies showed that mutations in 
MLL1, MLL3 and MLL4 and reduced expression of MLL3 and MLL4 had a 
better prognosis and outcome in PDAC (Dawkins et al. 2016). In contrast, high 
levels of KDM1A in PDAC is associated with poor survival. Also, several other 
KDMs (KDM2A, KDM3A, KDM5B) are highly expressed in various cancers 
(McGrath and Trojer 2015). Histone methyltransferases represent another class 
of attractive druggable targets for PDAC intervention. BRD-4770, a molecular 
inhibitor of G9a was found to decrease methylation levels, induce cell cycle 
arrest and mediate cell senescence (Artal-Martinez de Narvajas et al. 2013; 
Yuan et al. 2012).  Another G9a inhibitor, BIX-01294, also showed similar 
results in vitro in pancreatic cancer (Cui et al. 2015). One of the early 
nonselective KDM1 inhibitors, tranylcypromine, is approved by the FDA for 
neural disorders (Thinnes et al. 2014). Several compounds are being tested for 
the development of selective KDM inhibitors (G. A. Lomberk, Iovanna, and 
Urrutia 2016). 
 
 PRC2 complex 
The protein complex families - trithorax group (trxG) genes and polycomb group 
(PcG) genes were initially discovered in Drosophila Melanogaster, where they 
regulate the expression of homeotic genes (Hox genes) during the formation of 
body plan (Deschamps et al. 1999). They work antagonistically with trxG 
maintaining and PcG silencing transcription processes, respectively (Kennison 
1995; Schuettengruber et al. 2007). PcG assembles into two types of 
multiprotein complexes- Polycomb Repressive Complex 1 (PRC1) and 
Polycomb Repressive Complex 2 (PRC2) (Sauvageau and Sauvageau 2010). 
The PRC2 complex mediates H3K27me3 which is then recognized by 
members of the PRC1 complex, which further mediates H2AK119Ub1. This 







Figure 3: Schematic illustrating the function mediated by the PRC2 complex 
The core subunits of the PRC2 complex are Enhancer of Zeste 2 (EZH2), Suppressor 
of Zeste 12 (SUZ12), Embryonic ectoderm development (EED) and Retinoblastoma 
binding proteins 4 and 7 (RBBP4/7). The complex mediates addition of three methyl 
groups on lysine 27 of histone H3 (H3K27me3) subsequently switching the chromatin 
from an active transcription state to a repressive state. 
 
The PRC2 complex consists of four core members - Enhancer of Zeste 2 
(EZH2),  Embryonic ectoderm development (EED), Supressor of Zeste 12 
(SUZ12) and Retinoblastoma binding proteins 4 and 7 (RBBP4/7) as well as 
other accessory proteins (AEBP2, PCL, JARID2) (Aranda, Mas, and Di Croce 
2015). EZH2 is the SET domain-containing catalytic subunit of the complex 
which mediates H3K27me3. (Müller et al. 2002) WD40 domain harboring 
component, EED, recognizes the trimethylated residues and zinc finger 
containing subunit, SUZ12, maintains the enzymatic activity of EZH2 (van 
Mierlo et al. 2019). The additional accessory proteins modulate the PRC2 




mammals have two - EZH1 and EZH2 which are paralogs. Even though both 
EZH1 and EZH2 harbor H3K27me3 activity, PRC2-EZH1 shows relatively lower 
methyltransferase activity than PRC2-EZH2. Also, EZH2 is mostly present in 
proliferating cells whereas EZH1 is found in dividing cells (Margueron et al. 
2008). Genome-wide studies in human embryonic fibroblast cells show that 
PRC2 and H3K27 methylation mark co-occupy on several differentiation-
associated genes (Bracken et al. 2006). 
 Regulation of EZH2 expression in cancer  
EZH2 is an extensively studied SET domain-containing histone 
methyltransferase, which silences gene expression by catalyzing trimethylation 
of H3K27 (Chou et al. 2015). EZH2 dysregulation is frequently seen in a wide 
variety of cancers. Altered EZH2 expression and activity can be caused by 
activating/inactivating mutations of EZH2 which are primarily found in 
hematological malignancies (Jankowska et al. 2011; Morin et al. 2010) or by 
missense mutation (K27M) in H3.3 which is found in pediatric gliomas (Khuong-
Quang et al. 2012). Besides these genetic events targeting EZH2, in solid 
tumors the histone methyltransferase is mostly overexpressed. Overexpression 
of EZH2 can also be caused by various transcriptional pathways. For example, 
the Mitogen-activated protein kinase kinase (MEK) – extracellular signal-
regulated kinase (ERK) – ETS Like-1 (ELK1) pathway has been shown to be 
responsible for increased EZH2 expression in ERBB2 overexpressing and 
triple-negative breast cancers. Phosphorylated ELK1 binds to its binding motif 
on the EZH2 promoter thereby activating EZH2 transcription (Fujii et al. 2011). 
Another pathway involved in EZH2 regulation is Retiniblastoma protein (pRb) - 
E2F signaling. Upon phosphorylation of pRb, E2F dissociates from the pRb-
E2F complex, binds to its binding site on the EZH2 promoter thereby promoting 
EZH2 transcription (Margueron et al. 2008). Abberation of the pRb-E2F 
pathway or E2F overexpression is associated with EZH2 overactivation in 
breast and bladder tumors (Feber et al. 2004; Margueron et al. 2008). Cancer-
related transcription factors bind on the EZH2 promoter and activate its mRNA 
expression. In breast cancer, hypoxia inducible factor 1a (HIF1a) induced by 
the hypoxic environment binds to its consensus sequence on EZH2 and 




2016). Besides, miRNAs downregulate EZH2 levels by post-translational 
modifications. Many different miRNA s like miR-25, -98, -124, -138, -214 
interact with specific sequences in the EZH2 3’ untranslated region (3’ UTR) 
(Völkel et al. 2015). Together, aberrant EZH2 expression in cancer can be 
caused by various mechanisms which occur at different regulatory levels.   
 Context-dependent roles of EZH2 
EZH2 overexpression was initially detected in breast and prostate cancer 
through microarray analysis where it was strongly correlated with poor 
prognosis and associated with high-grade metastatic stages (Bachmann et al. 
2006; Varambally et al. 2002). High levels of EZH2 are reported in a wide 
variety of other cancers like melanoma (Fan et al. 2012; Zingg et al. 2015), lung 
(Hussain et al. 2009), hepatocellular (Sudo et al. 2005), bladder (Raman et al. 
2005), ovarian (Moses and Jia 2013; Rao et al. 2010), brain (Bracken et al. 
2003) and pancreatic cancer (Han et al. 2016; Ougolkov, Bilim, and Billadeau 
2008; Toll et al. 2010). In these solid tumor entities EZH2 mainly serves as an 
oncogenic factor by silencing tumor suppressor genes via H3K27me3-mediated 
transcriptional repression. However, apart from its PRC2-dependent activity, 
EZH2 exhibits various other modes of action depending on the cellular context. 
For instance, EZH2 mediates posttranslational methylation of many non-histone 
proteins like GATA4 (He et al. 2012), RORα (Lee et al. 2012) and TALIN 
(Gunawan et al. 2015). In addition to mediating gene repression, EZH2 also 
functions in a PRC2 independent manner to mediate transcriptional activation. 
In the estrogen receptor-positive luminal-like breast cancer cell line MCF7 for 
example, EZH2 mediates CYCLIND1 and MYC transcription independent of its 
methyltransferase activity (Shi et al. 2007). Another instance where EZH2 
functions as an activator is in castration-resistant prostate cancer. EZH2 acts 
via its methyltransferase activity but without relying on other PRC2 complex 
members. In this case, EZH2 gets phosphorylated posttranslationally at serine 
21, and then biochemically interacts with the androgen receptor to work as a 
transcriptional coactivator activating downstream target genes (K. Xu et al. 
2012).  
While the aforementioned examples highlight the oncogenic activity of EZH2,  




methyltransferase. For instance, Ntziachristos et al. found that loss-of-function 
EZH2 mutations promote tumor progression in T-cell acute lymphoblastic 
leukemia (T-ALL) (Ntziachristos et al. 2012). In another study, Bremer et al. 
demonstrated that high EZH2 expression significantly correlated with favorable 
prognosis in colorectal cancer (CRC) patients (Bremer et al. 2019). Another 
example is in renal cell carcinoma where loss of EZH2 mediates HIF-
dependent CXCR4 activation consequently promoting cancer metastasis 
(Vanharanta et al. 2013).  
Context-dependent EZH2 activities have also been described in the pancreas 
where EZH2 is critically involved in the regulation of cellular plasticity. 
Accordingly, EZH2 has been described as a critical regulator of acinar cell 
regeneration following injury. Mallen-St. Clair et al. showed that EZH2 
represses CDKN2A (encoding for the negative cell cycle regulator p16), thus 
allowing the proliferation of ADM which is a prerequisite for acinar 
redifferentiation (Mallen-St. Clair et al. 2012). Further mechanistic analyses 
suggest that EZH2-driven pancreatic regeneration critically involves 
transcriptional repression of the NFATc1 gene (N. M. Chen et al. 2017). The 
inflammatory transcription factor Nuclear factor of activated T cells (NFATc1) is 
activated upon acinar cell injury and blocks pancreatic regeneration. In KRAS 
wildtype cells, EZH2 counteracts NFATc1 activity by binding to the TSS of the 
NFATc1 gene and transcriptionally repressing its expression, which then allows 
the redifferentiation of acinar cells in later stages of pancreatic recovery. 
However, the EZH2-NFATc1 axis does not operate in the same way in the 
context of PDAC. In the presence of oncogenic KRAS, EZH2 transcriptionally 
activates NFATc1 expression, which further leads to ADM formation and 
progression into PDAC. Hence, KRAS acts as a switch that regulates opposing 
roles of EZH2 in acinar cell regeneration vs. transformation (N. M. Chen et al. 
2017). 
Overall, EZH2 activity are highly context dependent. While EZH2 is crucial 
during development and regeneration of the organ, it shifts its role in cancer. It 
functions via various modes of action, promotes either oncogenic or tumor-





 EZH2 in PDAC 
EZH2 was identified as an oncogenic driver in PDAC by Ougolvou and 
colleagues, where they found nuclear overexpression of the histone 
methyltransferase in 68 % of PDAC patients. They elegantly provide functional 
insights into the role of EZH2 in mediating cell proliferation and 
chemoresistance. Their study also reported that EZH2 silencing induced 
apoptosis and increased the sensitivity towards gemcitabine and doxorubicin 
(Ougolkov, Bilim, and Billadeau 2008). Another report in 2012 by Toll et al. 
supported this study and reported that EZH2 depletion sensitizes pancreatic 
cancer cells to gemcitabine and subsequently induces apoptosis. They 
evaluated EZH2 levels in PDAC samples from patients treated with 
gemcitabine. Patients with low EZH2 levels survived for a significantly longer 
time compared to the ones with high EZH2 levels. This validates the correlation 
between high EZH2 levels and low gemcitabine response. Furthermore, their 
study was the first to show that high EZH2 levels are associated with reduced 
E-cadherin levels in PDAC (Toll et al. 2010). The EZH2-E-cadherin axis was 
further validated by Han et al., where they additionally showed that EZH2 
mediates cell invasion and migration by transcriptionally repressing CDH-1. In 
their study, patients harboring an abundance of EZH2 and low E-cadherin 
displayed lower survival (Han et al. 2016). Altogether, EZH2 is highly 
expressed and harbors oncogenic activity in pancreatic cancer. 
 EZH2 inhibitors 
Considering that H3K27me3 is one of the frequently dysregulated histone 
modifications in a lot of cancers including PDAC, and EZH2 is the mediator for 
depositing this mark, it has been a major target for the development of 
inhibitors. One of the first inhibitors developed for EZH2 inhibition was 3-
deazaneplanocin (DNZep), an S-adenosyl-L-homocysteine (SAH) hydrolase 
inhibitor, which increases SAH levels, thereby leading to inactivation of several 
methyltransferases including EZH2. It showed promising activity in breast 
cancer and prostate cancer diminishing EZH2 and H3K27me3 levels and 
restoring downstream target genes of PRC2 (Tan et al. 2007). This small 
molecule inhibitor also reduced the self renewal capacity of prostate, ovarian 




that DNZnep boosted the antiproliferative effect of gemcitabine in PDAC cell 
lines and primary cultures derived from PDAC tumors. Despite this, the use of 
this drug has been terminated due to its high toxicity levels (Gaudichon et al. 
2014). 
Following this up, S-adenosyl-L-methionine (SAM) competitive EZH2 inhibitors 
like EPZ005687, GSK2816126, CPI-1205, UNC1999 and EPZ6438 
(tazemetostat) were discovered through high throughput screening approaches. 
They display 1000 times more selectivity for EZH2 over other 
methyltransferases and can effectively antagonize EZH2 activity in the 
nanomolar range (McGrath and Trojer 2015). GSK126 was effective in 
monolayers in gastric cancer and lung adenocarcinoma cell lines as well as in 
xenografts models of lymphoma, where it displayed a decrease in cell 
proliferation, angiogenesis, and a significant increase in apoptosis (Y. T. Chen 
et al. 2016; McCabe et al. 2012). The compound CPI-1205 exhibited a 
decrease in EZH2 and H3K27me3 levels. Additionally, it displayed 
antiproliferative effects and led to increased apoptosis in vitro in 
medulloblastoma. It is relatively well tolerated and currently in clinical trials for 
medulloblastoma and B cell lymphoma (Miele et al. 2017; Vaswani et al. 2016). 
UNC1999, an orally bioavailable EZH2 inhibitor induced durable tumor 
response successfully in monolayers, spheroid cultures and pdx mouse models 
of PDAC (Huang et al. 2015b). Tazematostat (EPZ6438) is a first in class, 
highly selective, orally administered EZH2 inhibitor that has been tested in a 
phase-I study. It exhibited beneficial results with a favorable safety profile and 
anti-tumor activity in patients with B cell non-Hodgkin lymphoma and 
SMARCA4-negative or INI1 negative advanced solid tumors (Italiano et al. 
2018; Richart and Margueron 2020). Moreover, a disease control rate of 55 % 
was observed in solid tumors with this epidrug. Currently, Tazematostat is in 
phase-II clinical trials (NCT01897571) (Hessmann et al. 2017). To date, three 
EZH2 inhibitors, CPI-1205, GSK2816126 and tazematostat (EPZ 6438) have 






Figure 4: EZH2 SET-domain inhibitors and their mechanism of action. 
The catalytic unit of the PRC2 complex, EZH2, harbours a Su(var)3-9,EZH2 and 
Trithorax (SET) domain which catalyzes the transfer of methyl groups from the methyl 
donor S-Adenosyl-L-methionine (SAM) to H3K27, thus leading to transcriptional 
repression. The competitive SAM inhibitors (belonging to a class of EZH2 inhibitors) 
block the methylation process, thus keeping the chromatin in an active transcriptional 
state. (Adapted from (Gulati, Béguelin, and Giulino-Roth 2018)). 
  
 
Although EZH2 has a more prominent role in mediating H3K27me3, EZH1 
contributes to maintaining the methylation levels. Hence, studies suggest that 
dual inhibitors like DS-3201, which simultaneously inhibit both EZH1 and EZH2, 
are more effective (Honma et al. 2017). The same report also argues that a 
combination of EI1 and EED-226, which are EZH2 and EED inhibitors, 
respectively increased the treatment efficacy compared to monotherapies. Most 
recently, an EZH2 degrader has been characterized which efficiently degrades 
EZH2 protein making this compound highly specific for EZH2. Furthermore, this 
is a valuable epidrug for cancers where EZH2 plays a methyltransferase 
independent role (Ma et al. 2020).  
The majority of these small molecule inhibitors of EZH2 exhibit an optimistic 




Paradise, Barham, and Fernandez-Zapico 2018). But the combination of these 
inhibitors with a chemotherapeutic agent or another epidrug seems to work 
better in PDAC than a monotherapy (Honma et al. 2017; Ougolkov, Bilim, and 
Billadeau 2008). Further exploration of these inhibitors in larger clinical trials as 
targeted therapy is necessary for maximizing its benefits for translational utility. 
Furthermore, given that EZH2 exhibits a highly context-dependent expression 
and function, inhibiting EZH2 might not be benefical in all situations or might 
even foster cancer progression. Indeed, some studies demonstrate that EZH2 
inhibitors were only effective in subgroups of cancer patients. For instance, 
Puppe et al. showed in 2009 that EZH2 inhibition by DZNep was selectively 
beneficial in BRCA-1 deficient or mutated breast cancer cells as these cells 
promoted tumor progression in an EZH2 dependent manner whereas BRCA-1 
proficient cells were not affected by EZH2 inhibition (Puppe et al. 2009). In 
certain subsets of breast cancer (Shi et al. 2007), EZH2 mediates tumor 
progression in a methyltransferase independent manner and in such cases 
inhibitors blocking the SET domain of EZH2 would not be efficacious while 
inhibitors that degrade EZH2 protein would potentially be more effective (Ma et 
al. 2020). Besides, another study suggests that while inhibiting EZH2 in 
cancers harboring EZH2 Gain-of-function (GOF) mutations like in follicular 
lymphomas (FL) and Diffuse large B cell lymphomas (DLBCL) is very effective, 
the inhibitors were not useful in cells harboring EZH2 Loss-of-function (LOF) 
mutations like in certain cases of Myeloproliferative neoplasms (MPN) and T-
cell acute lymphoblastic leukemia (T-ALL) (Honma et al. 2017). Further several 
lines of evidence demonstrate that blocking EZH2 is specifically impactful in 
cancer cells harboring mutation or loss of SWI/SNF subunits – in lung cancer 
cells (K. H. Kim et al. 2015), small cell carcinoma of ovary (Chan-Penebre et al. 
2017) and other rhaboid tumors (Knutson et al. 2013; Wilson et al. 2010). 
These studies argue that it is necessary to understand the molecular conditions 
underlying EZH2 mediated tumor progression in cancer before designing 





 Aims of the study 
EZH2 consitutes  a widely studied epigenetic factor in development as well as 
in cancer. Its implications in various cancer types including PDAC characterize 
the histone methyltransferase as a promising therapeutic target in PDAC. 
However, recent findings also suggest that the activity, target gene selection 
and regulation of chromatin regulatory proteins like EZH2 occur in a highly 
context-dependent manner. Hence, the successful application of EZH2 
inhibition in PDAC treatment requires an in-depth understanding of how the 
histone methyltransferase promotes PDAC progression and depends on the 
elucidation of the molecular dependencies determining the efficacy of EZH2 
inhibition in PDAC. 
In this study, we aim at investigating the role of EZH2 in pancreatic cancer  
progression and plasticity and aim at gaining mechanistic insights into EZH2-
dependent gene regulation in PDAC. Our specific aims are: 
1) To dissect the functional implications of EZH2 in PDAC development and 
progression.  
2) To identify EZH2-dependent gene signatures in PDAC progression. 
3) To elucidate the molecular prerequisites determining the efficacy of EZH2 







2  MATERIALS 
 Equipments: 
EQUIPMENT COMPANY 
Agarose electrophoresis chamber 
Peqlab Biotechnologie GmbH, 
Erlangen, Germany 
Arium®pro ultrapure water system Sartorius, Göttingen, Germany 
Aspirator with trap flask Grant Instruments Ltd, Cambs, 
England 
Bioanalyzer ( 2100, 5067-4626) Agilent technologies, USA 
Biorupter® Pico Diagenode, Liege, Belgium 
Class II safety cabinet (S2020 -1.2) Thermo Fisher Scientific, Waltham, 
USA 
Cold plate (Histocore Arcadia c) Leica Biosystem, Wetzlar, Germany 
Dri-Block Heater DB2A Techne, Staffordshire, UK 
Fluorescence Microscope System  Leica Camera, Wetzlar, Germany 
gentleMACS dissociator Miltenyi Biotech, Germany 
Heating plate Leica Biosystem, Wetzlar, Germany 
HERAcell 240i CO2 incubator Thermo Scientific, Waltham, USA  
Ice flaker (AF80) Scotsman, Edinburgh, UK 
INTAS- ECL Chemostar imager INTAS Science Imaging Instruments 
GmbH, Göttingen, Germany 
Inverted microscope (CKX53SF) Olympus, Tokyo, Japan 
Light microscope "BX43" Olympus, Tokyo, Japan 
Magnetic stirrer (RH B S000) IKA®Laboratory equipment, Germany  
Microplate Luminometer "LUMO" Autobiolabtec Instruments Co.,Ltd, 
China 
Microplate reader "PHOmo" Autobiolabtec Instruments Co.,Ltd, 
China 
Microwave (NN-E209W) Panasonic; Japan  
Microtome (Leica RM2265) Leica Biosystems, Wetzlar, Germany 
Mini-PROTEAN Tetra Cell Bio Rad Laboratories, Hercules, USA 
MSA Minishaker IKA, Staufen, Germany 







Multipette plus Eppendorf, Hamburg, Germany 
NanoPhotometer P-330 Intas Science Imaging Instruments, 
Goettingen, Germany 
Neubauer chamber Assistant, Sondheim/Rhön, Germany 
Paraffin Tissue embedder (EG1150H) Leica Biosystems, Wetzlar, Germany 
pH meter (FiveEasyTM Plus FEP20) Mettler-Toledo AG, Schwerzenbach, 
Switzerland 
PerfectSpin 24R Refrigerated 
Microcentrifuge  
Peqlab, Erlangen, Germany 
Pipetboy acu 2 INTEGRA Biosciences, Biebertal, 
Germany 
PowerPac Basic Power Supply Bio Rad Laboratories, Hercules, USA 
Precision balance PCB  Kern & Sohn, Balingen, Germany 
PSU-20i Orbital Shaking Platform Grant Instruments, Shepreth, UK 
Refrigerator 4°C (Comfort) Liebherr, Bulle, Switzerland 
Safe 2020 Class II Biological Safety 
Cabinets 
Thermo Fisher Scientific, Waltham, 
USA 
SequenzaTM slide rack(cadenza 
system) 
TED PELLA,INC, Redding, CA 
Shandon coverplateTM (cadenza 
system) 
Thermo Scientific, Waltham, USA  
Sprout Minicentrifuge Biozym Scientific, Hessich Oldendorf, 
Germany 
StepOnePlus Real-Time PCR System Thermo Fisher Scientific, Waltham, 
USA 
Thermomixer 5436 Eppendorf, Hamburg, Germany 
Tissue dehydration machine  Leica Biosystems, Wetzlar, Germany 
Trans-Blot Turbo Transfer System Bio Rad Laboratories, Hercules, USA 
TX-400 4 x 400mL Swinging Bucket 
Rotor 
Thermo Fisher Scientific, Waltham, 
USA 
Universal Oven UN55 Memmert, Schwabach, Germany 
VacuuHandControl VHCpro Vacuumbrand, Wertheim, Germany 
Vacuum pump: BVC Control Vacuumbrand, Wertheim, Germany 
Waterbath (WNB14) MemmertGmbH+Co. KG, Schwabach, 
Germany 





Qubit (Q32854) Fluorometer Invitrogen GmbH, Karlsruhe 
-20°C freezer Liebherr, Bulle, Switzerland 
-80°C Ultra low temperature freezer 
(MDF-U54V) 
Sanyo electric Co.,Ltd Japan 
 
 Consumable materials 
MATERIALS COMPANY 
Centrifuge tube 15 and 50 ml Sarstedt, Nümbrecht, Germany 
Cell culture Inserts - 8um pore size 
(BD 353097) 
Falcon, Germany 
Cell strainer-100µm Falcon, Durham, USA 
Cell scrapper Sarstedt, Nümbrecht, Germany 
Cello meter counting chamber Nexcelom Bioscience, Lawrence, MA 
Cryo pure vial Sarstedt, Nümbrecht, Germany 
Combitips advanced (Multipipette tips) Starlab International GmbH, Hamburg, 
Germany 
Graduated sterile pipettes (2,10,25 
and 50ml) 
Greiner bio-one, Frickenhausen, 
Germany 
Glass coverslips (24×32, 24×60) Menzel Gläser
®, Menzel GmbH+Co 
KG, Braunschweig, Germany  
Micropipette filter tips Starlab International GmbH, Hamburg, 
Germany 
Micropipette tips  Starlab International GmbH, Hamburg, 
Germany 
Microtome blade (S35) Feather safety Razer Co. Ltd, Osaka, 
Japan 
Microtube (1.5 and 2ml) Sarstedt, Nümbrecht, Germany 
Injection needle (Sterile) B.Braun, Melsungen, Germany 
Nitrocellulose membrane GE Healthcare lifesciences, 
Marlborough, USA 
Parafilm Pechiney plastic packaging, Chicago, 
USA 
PCR tubes Sarstedt, Nümbrecht, Germany 
Scalpel Feather safety Razer Co. Ltd, Osaka, 
Japan 







Sponge Pad For XCell IITM Blotting Novex by Life technologies, Carlsbad, 
CA 
Superfrost glass slides (Histology) Thermo Scientific, Waltham, USA  
Syringe (1ml) BD Plastic, Madrid, Spain 
Syringe (5,10,20ml) B.Braun, Melsungen, Germany 
Sterile syringe Filter (0.2µm) Labsolute, Th.Geyer ingredients 
GmbH & Co.KG, Höxter, Germany  
Tissue culture multiwell plates  Greiner bio-one, Frickenhausen, 
Germany 
Tissue culture flasks Greiner bio-one, Frickenhausen, 
Germany 
Tissue culture dishes (2cm, 10cm) Sarstedt, Nümbrecht, Germany 




Albumin standard Thermo Scientific, Waltham, USA 
Agarose Biozym Scientific GmbH, Oldendorf, Germany 
Aqua  B.Braun, Melsungen, Germany 
Bovine serum albumin (BSA)  Serva, Heidelberg, Germany 
β-Mercaptoethanol Merck, Darmstadt, Germany 
Citric acid monohydrate Carl Roth GmbH Co. KG, Karlsruhe, Germany 
EDTA Acros organics, Geel, Belgium 
EGTA Sigma-Aldrich, St. Louis, USA 
Ethanol ChemSolute
®, Th.Geyer ingredients GmbH & 
Co.KG, Höxter, Germany 
Eosin Sigma-Aldrich, St. Louis, USA 
Formaldehyde (4%) Merck, Darmstadt, Germany 
HEPES  Carl Roth GmbH Co. KG, Karlsruhe, Germany 
Glycerol Carl Roth GmbH Co. KG, Karlsruhe, Germany 
Hematoxylin Sigma-Aldrich, St. Louis, USA 
Hydrochloric acid  Carl Roth GmbH Co. KG, Karlsruhe, Germany 





Isofluran AbbVie Deutschland GmbH & Co. KG, 
Ludwigshafen, Germany 
Methanol Carl Roth GmbH Co. KG, Karlsruhe, Germany 
Non-fat milk powder Carl Roth GmbH Co. KG, Karlsruhe, Germany 
PBS (Dulbecco's) Biochrom, Berlin, Germany 
PMSF Sigma-Aldrich, St. Louis, USA 
Roticlear Carl Roth GmbH Co. KG, Karlsruhe, Germany 
Rotimount Carl Roth GmbH Co. KG, Karlsruhe, Germany 
Saline (0,9% NaCl) B.Braun, Melsungen, Germany 
Sodium chloride Merck, Darmstadt, Germany 
Sodium citrate Sigma-Aldrich, St. Louis, USA 
Sodium hydroxide Acros organics, Geel, Belgium 
Sodium pyrophosphate Sigma-Aldrich, St. Louis, USA 
Sodium pyruvate Gibco®Thermo scientific, Waltham, USA 
Tris-HCl Carl Roth GmbH Co. KG, Karlsruhe, Germany 
Tris- base Carl Roth GmbH Co. KG, Karlsruhe, Germany 
Triton X-100 Sigma-Aldrich, St. Louis, USA 
TRIzol QIAGEN GmbH, Germany 
Tween-20 Sigma-Aldrich, St. Louis, USA 
 
 Kits, reagents and inhibitors 
KITS/REAGENTS/INHIBITORS COMPANY 
Agarose A Beads  Merck Millipore, Billerica, USA 
Agarose G Beads  Merck Millipore, Billerica, USA 
iScript cDNA Synthesis Kit Bio Rad Laboratories, Hercules, USA 
iTaq Universal SYBR Green Supermix Bio Rad Laboratories, Hercules, USA 
Midori green Nippon genetics Europe GmbH 
Bradford reagent Bio Rad Laboratories, Hercules, USA 
Western Lightning ECL/ ECL Ultra Perkin Elmer, USA 
Lipofectamine 2000 Invitrogen, USA 






MycoAlert Mycoplasma Detection Kit Lonza Group, Basel, Switzerland 
MicroPlex Library Preparation Kit Diagenode, Liege, Belgium 
True seq RNA Library Preparation Kit Illumina, USA 
Trans-Blot Turbo RTA Midi 
Nitrocellulose Transfer Kit 
Bio Rad Laboratories, Hercules, USA 
Peroxidase Rabbit/Mouse IgG 
Vectastain ABC kits   
Biozol GmbH, Germany 
BrdU cell proliferation kit Roche, 11647229001, Germany 
cOmplete™ protease inhibitor cocktail Roche, 11697498001, Germany 
Tazemetostat/EPZ6438  ChemieTek, USA 
DAB ImmPACT VECTOR Laboratories LTD., UK 
Matrigel GF R Red/F 10 ml Thermo Geyer GmbH&Co KG, 
Germany 
DAPI Sigma-Aldrich, St. Louis, USA 
Ponceau solution Sigma-Aldrich, St. Louis, USA 
ImmuMount Thermofisher, Waltham, USA 
 
 Nucleic acids 
 gRNA sequences and validation primers for CRISPR/Cas9-mediated 
EZH2 knockout 



























 siRNA/shRNA oligonucleotides 
siRNA/shRNA TARGET SEQUENCE (5-3) SOURCE 
siEZH2 #1 GGAUACAGCCUGUGCACAUTT Ambion,Carlsbad,USA 
siGATA6 #1 CCUCUGCACGCUUUCCCUATT Ambion,Carlsbad,USA 
siGATA6 #2 GGCUCUAUAUGAAACUCCATT Ambion,Carlsbad,USA 
shGATA6 #1 CCACTACCTTATGGCGTAGAA Mission (Sigma) 
shGATA6 #2 CTGTCCCTATGACTCCTACTT Mission (Sigma) 
 
 qPCR primers 
GENE SEQUENCE SPECIES 
Ezh2 FP CAACCCGAAAGGGCAACAAA Mouse 
Ezh2 RP ACCAGTCTGGATAGCCCTCT Mouse 
Gata6 FP CTTTGCGGGCTCTATATGAAACTCCAT Mouse 
Gata6 RP TAGAAGAAGAGGAAGTAGGAGTCATAGGGACA Mouse 
Trnp1 FP TCATCTACGCGGAGGAGTCA Mouse 
Trnp1 RP AGCCTCTGAGGAGCTTAGTGT Mouse 
Gata4 FP CTGTCATCTCACTATGGGCAC Mouse 
Gata4 RP GAGTGACAGGAGATGCATAGC Mouse 
Iqgap2 FP AGCCTCTGAGGAGCTTAGTGT Mouse 
Iqgap2 RP ATGAGGCTTCTGCCATCGAC Mouse 
Fam117a FP CACGGTAACAAAGCCTCCTCT Mouse 
Fam117a RP GGCTCCCGTTTGAAGACGTA Mouse 
Pde3b FP TCACAAGGGATTGAGTGGCAG Mouse 
Pde3b RP AGGCCCATTTAGGTGGCATC Mouse 
Inhbb FP ATCAGCTTTGCAGAGACAGATGG Mouse 
Inhbb RP CTCCGTGACCCTGTTCTTGG Mouse 
Sox12 FP TCGTCTAGTATCGCCGACC Mouse 
Sox12 RP GCCCCAATACCTGATTCCTG Mouse 
Creb1 FP CCTTGGGATATTACAGAAGCTGGAT Mouse 
Creb1 RP CCCTTTAGGCATATTACCTTTGGGA Mouse 





GENE SEQUENCE SPECIES 
Sfrp1 RP AGTTGTGGCTGAGGTTGTCC Mouse 
Klhl23 FP CGAGCCCACACCCAGAATATG Mouse 
Klhl23 RP TCATGATGACAGCCCCACAC Mouse 
Foxa2 FP ATCCGCCACTCTCCTT Mouse 
Foxa2 RP CAGTGCCAGTTCTCAC Mouse 
Tspan8 FP GAAGGAAAAGAATCTGCAGGCAC Mouse 
Tspan8 RP AGTCCGTAGAAGGCTGTCCT Mouse 
Hdhd3 FP TCTTTTCCCGAGCCAGGATCT Mouse 
Hdhd3 RP TGTAGGTCAGAGGGGTAGGC Mouse 
Ralgps1 FP GATGGCTAGCGTGTTGGTCA Mouse 
Ralgps1 RP GCCAACTCGGCAAACTCCT Mouse 
Txndc16 FP GAGGGGCATCTTGAAGGCAT Mouse 
Txndc16 RP GCAGACAAGACTGTGATGGGA Mouse 
Cxadr FP AGCCGAGATCGTTTACCTGC Mouse 
Cxadr RP ACTGGTGAAATCCGCGATCC Mouse 
Fcgrt FP ATTAAATGGTCAGAAGAGGGGGAC Mouse 
Fcgrt RP CTCCTCACCATTGAGGGCAAA Mouse 
Tgfbr3 FP CCTCCGCAGTACAGACCAAG Mouse 
Tgfbr3 RP CCTCCGAAACCAGGAAGAGTC Mouse 
Tmem51 FP CTTCGGGATCTCTCGTCTGC Mouse 
Tmem51 RP TCACAGCGGAAAGTCATCCG Mouse 
Sort1 FP CTGACAACAAATGGGTACCGGA Mouse 
Sort1 RP AGCTGGATTCTGGGACAAGC Mouse 
RplpO FP TGGGCAAGAACACCATGATG Mouse/ 
Human 
RplpO RP AGTTTCTCCAGAGCTGGGTTGT Mouse 
/Human 
EZH2 FP AAAGAACTCACCGAACAGCA Human 
EZH2 RP CAGAAAAGCGTATGAAAGGAGTG Human 
GATA6 FP TCTACAGCAAGATGAATGGCC Human 





 ChIP Primers 
GENE SEQUENCE SPECIES 
Gata6 TSS/exon FP AAAAAGCGGCGGTTTCGTTT Mouse 
Gata6 TSS/exon RP GCCTCGGTGAAGAGAGTTCC Mouse 
Gata6 intragenic FP GAGGTCCAAGATCATGTGGCA Mouse 
Gata6 intragenic RP TAGCACTGATTGCCCAAGCC Mouse 
Trnp1 TSS/exon FP AGTCAACAACACCGCACCTT Mouse 
Trnp1 TSS/exon RP TCATCTACGCGGAGGAGTCA Mouse 
Trnp1 intragenic FP AGAGTGGAGCCTCTGAGGAG Mouse 
Trnp1 intragenic RP GTAGAAGTTCTGGGTGGGGC Mouse 
Gata4 TSS/exon FP TCCACCAGCCCAGGAGTTTA Mouse 
Gata4 TSS/exon RP GGAGTGGGAAGAAGTGTCGG Mouse 
Gata4 intragenic FP CCAGTGGAAGGGTCGGTAAC Mouse 
Gata4 intragenic RP TCCCATTCTTGACAAGTGAGGC Mouse 
Iqgap2 TSS/exon FP GCTCCTCACCTGATACCCCTA Mouse 
Iqgap2 TSS/exon RP TAAGTCCCTCCACCTCGCAA Mouse 
Iqgap2 intragenic FP AGCCCTGACTAGGTCAATCCC Mouse 
Iqgap2 intragenic RP GGGGCCCTTCAATCCTAACC Mouse 
Fam117a TSS/exon FP AACCGAAAAGTGGTCCGAAGT Mouse 
Fam117a TSS/exon RP CAACACTCCTTGCACGCAC Mouse 
Fam117a intragenic FP ATTGCACCTGAGCTGCGT Mouse 
Fam117a intragenic RP CCTTGAGGGCAGAAGGTTCC Mouse 
Pde3b TSS/exon FP CGAGTACCGCGGAGGAAAAA Mouse 
Pde3b TSS/exon RP ATAGTAACCGGCTGCGCTTT Mouse 
Pde3b intragenic FP TAGTCCTGTGTTGGCTCCGT Mouse 
Pde3b intragenic RP CACCGTCTTCAGTAACTGCCA Mouse 
Inhbb TSS/exon FP GATGCCAGGCCACTTTTGC Mouse 
Inhbb TSS/exon RP TGCCATTTATCCATCGCCCC Mouse 
Inhbb intragenic FP GAATCGTTTGGCCTTTCCGC Mouse 
Inhbb intragenic RP AACTGACAGGTCACTGGTGC Mouse 
Sox12 TSS/exon FP CGATACTAGACGAGCGCCAG Mouse 





GENE SEQUENCE SPECIES 
Sox12 intragenic FP GGCCCTTGTAAGTCAGGTCC Mouse 
Sox12 intragenic RP GGTCCCCATCAAGCAACCAT Mouse 
Creb1 TSS/exon FP GACGCTCCCTCCAGAATGAC Mouse 
Creb1 TSS/exon RP ATGACGCCTCTCGGAACAAC Mouse 
Creb1 intragenic FP AGGTGTGGCTTACTTTGCAGTT Mouse 
Creb1 intragenic RP TGCTCTCTTTCTCTTGTGCCAAA Mouse 
Sfrp1 TSS/exon FP GCGAGTACGACTACGTGAGC Mouse 
Sfrp1 TSS/exon RP CGGGGGCTTGGTGTAGAAG Mouse 
Sfrp1 intragenic FP TGCAGAAACGAGCCAAAAGC Mouse 
Sfrp1 intragenic RP CAGGGCAAGGGTCTGACATT Mouse 
Klhl23 TSS/exon FP TTCTCTCCATCTTGGTGGCATC Mouse 
Klhl23 TSS/exon RP CAATTCGCCGTTGTTGGTTCT Mouse 
Klhl23 intragenic FP AATCCTGTGAGCTAGGGAGGT Mouse 
Klhl23 intragenic RP GTTAGATGGCTGATCTTGAACGATG Mouse 
 
 Buffers 
 ChIP Buffers 
2.6.1.1 Cross linking Buffer 
COMPONENT STOCK CONCENTRATION 
Formaldehyde 37 % 
PBS 1X 
 
2.6.1.2 Nelson lysis Buffer 
COMPONENT STOCK CONCENTRATION 
NaCl 150 mM 
EDTA pH 8 20 mM 
Tris pH 7.5 50 mM 
NP-40 0.5 % 
Triton-X-100 1 % 




2.6.1.3 Gomes lysis Buffer 
COMPONENT STOCK CONCENTRATION 
NaCl 150 mM 
NP-40 1 % 
Sodium deoxycholate 0.5 % 
Tris-HCl pH 8 50 mM 
EDTA 20 mM 
NaF 20 mM 
SDS 0.1 % 
 
2.6.1.4 Gomes Wash buffer 
COMPONENT STOCK CONCENTRATION 
Tris-HCl pH 8.5 100 mM 
LiCl 500 mM 
NP-40 1 % (v/v) 
Sodium deoxycholate 1 % (w/v) 
EDTA 20 mM 
NaF 20 mM 
 
2.6.1.5 Weinmann lysis buffer (WB) 
COMPONENT STOCK CONCENTRATION 
Tris-HCl (pH 8) 50 mM 
EDTA 10 mM 
SDS 1 % 
 
 Western Buffers 
2.6.2.1 Buffers for gels 
SOLUTION COMPOSITION AMOUNT 
Stacking gel buffer stock pH 
6.8 
Tris-base 0.5 M 
SDS 0.4 % (v/v) 





SOLUTION COMPOSITION AMOUNT 
Acrylamide 16 ml 
Aqua dest 25 ml 
Seperating gel buffer stock pH 
8.8 
Tris base 1.5 M 
SDS 0.4 % (v/v) 
Separating gel buffer (10 %) 
Seperating gel buffer stock 20 ml 
Acrylamide 26.6 ml 
Glycerol 4 ml 
Aqua dest 29.3 ml 
Separating gel buffer (15 %) 
Seperating gel buffer stock 20 ml 
Acrylamide 40 ml 
Glycerol 4 ml 
Aqua dest 16 ml 
 
2.6.2.2 Transfer buffer 
COMPONENT AMOUNT 
5X Transfer buffer 200 ml 
Ethanol 200 ml 
Water 600 ml 
 
2.6.2.3 Laemelli Buffer (5X) 
COMPONENT STOCK CONCENTRATION 
Tris-HCl pH 6.8 225 mM 
Glycerine 50 % 
SDS 5 % 
DTT 100 mM 
Bromophenol blue 0.02 % 






2.6.2.4 Running buffer 
COMPONENT STOCK CONCENTRATION 
Tris base 250 mM 
Glycine 1.92 M 
SDS 1 % (w/v) 
 
2.6.2.5 TBS 
COMPONENT STOCK CONCENTRATION 
NaCl 150 mM 
KCl 2.68 mM 
Na2HPO4x2HO 4.29 mM 
KH2PO4 (pH 7.4) 1.47 mM 
 
2.6.2.6 TBST 
COMPONENT STOCK CONCENTRATION 
TBS 1 X 
Tween 0.1 % (w/v) 
 
2.6.2.7 WCL Buffer 
COMPONENT STOCK CONCENTRATION 
HEPES pH 7.5 50 mM 
NaCl 150 mM 
EGTA 1 mM 
Glycerol 10 % (v/v) 
Triton X-100 1 % (v/v) 
NaF 100 mM 








2.6.2.8 Blocking solution 
COMPONENT STOCK CONCENTRATION 
TBST 1 X 
Skimmed milk 5 % (w/v) 
 
 Antibodies, Enzymes and standards 
 Antibodies 
2.7.1.1 Antibodies for ChIP and ChIP-Seq 
ANTIBODY COMPANY NUMBER 
EZH2 diagenode C15410039-classic 
H3K27me3 Cell Signaling 9733 
H3K4me3 Cell Signaling 9751 
H3K27ac Genetex GTX128944 
Rabbit IgG diagenode C15410206 
 
2.7.1.2 Antibodies for immunohistochemistry 
ANTIBODY COMPANY NUMBER DILUTION 
EZH2 (murine) Cell Signaling 5246 1:100 
EZH2 (human) Leica NCL-L-EZH2 1:300 
HA Cell Signaling 3724 1:100 
GATA6 R&D Systems AF1700 1:50 
H3K27me3 Cell Signaling 9733 1:200 
 
2.7.1.3 Antibodies for Western Blot 
ANTIBODY COMPANY NUMBER DILUTION 
EZH2 (murine) Cell Signaling 5246 1:100 
GATA6 R&D Systems AF1700 1:300 
H3K27me3 Cell Signaling 9733 1:1000 
H3 Abcam Ab1791 1:1000 




ANTIBODY COMPANY NUMBER DILUTION 
Anti-rabbit (IgG) 
HRP 
Cell Signalling 7074 1:10000 
Anti-mouse (IgG) 
HRP 
Cell Signalling 7076 1:10000 
Mouse Anti-goat 
(IgG) HRP 




Proteinase K AppliChem Panreac 




DNA ladder 100 bp Biolabs 
DNA ladder 1 kb ThermoFischer 
Protein prestained ruler Thermoscientific 
 
 Cell culture reagents, growth media and antibiotics 
PRODUCT COMPANY 
Dulbecco’s Modified Eagle Medium 
(DMEM) 
Thermo Fisher Scientific, Waltham, 
USA 
Fetal Calf Serum Biowest, Nuaille, France 
Non-Essential Amino Acids Solution 
(NEAA-100 X) 
Thermo Fisher Scientific, Waltham, 
USA 
Trypsin-EDTA (0.5 %) Thermo Fisher Scientific, Waltham, 
USA 
Puromycin GIBCO, Invitrogen GmbH, Darmstadt 









AUTOsoft 2.6 Autobio, Zhengzhou, China 
Leica Application Suite (LAS) X 
Software 
Leica Camera, Wetzlar, Germany 
Chemostar Software 
Intas Science Imaging Instruments, 
Goettingen, Germany 
StepOne Software Thermo Fisher Scientific, Waltham, 
USA 
ImageJ National Institutes of Health (NIH), 
USA 





This chapter describes the various methods followed towards performing the 
experiments and analyses of the acquired data. Studies were conducted with 
the assistance from and cooperation with different collaborators departments: 
Tumor grading was performed by Prof. Dr. med Philipp Ströbel, Institute of 
Pathology, University Medical Center, Goettingen. EZH2 and GATA6 Stainings 
in Tissue microarray (TMA) samples were provided by Dr. Stefan Kueffer 
(Institute of Pathology, University Medical Center, Goettingen). The generation 
of PDAC-PDX models was performed in close collaboration with Prof. Dr. med. 
Jochen Gaedcke (Department of General-, Visceral- and Pediatric surgery, 
University Medical Center, Goettingen) and Prof. Dr. med Phillip Ströbel 
(Institute of Pathology, University Medical Center, Goettingen). The 
caNFATc1;KrasG12D (NKC) and EZH2fl/+;caNFATc1;KrasG12D (ENKC) mouse 
models have been generated with support from Benjamin Steuber, Waltraut 
Kopp and Sercan Mercan. The shRNA EZH2 NKC cells were obtained from 
Jinsan Zhang (Gene Regulatory Mechanisms and Molecular Epigenetics Lab, 
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, USA). 
 In vivo experiments 
 Mouse strains  
caNfatc1;KrasG12D (NKC) mice have been previously described (Baumgart et al. 
2014).  Briefly, this model harbors the oncogenic KrasG12D mutation and 
pdx/p48 Cre-mediated expression of HA-tagged NFATc1 constitutively under 
the control of Rosa26 promoter. Ezh2fl/fl mice were purchased from Charles 
River and were interbred with caNfatc1;KrasG12D littermates to generate 
Ezh2fl/+;caNfatc1;KrasG12D (ENKC) mice. For survival studies, 
Ezh2fl/+;caNfatc1;KrasG12D (ENKC) mice were followed up until they reached 
end point criteria and then sacrificed. The pancreas, liver and spleen were 
collected in 4 % formaldehyde for histological analysis and a part of pancreatic 
tissue was frozen in -80 °C. The tissues collected and stored overnight in 4 % 
formaldehyde were subjected to dehydration in increasing concentrations of 




paraffin blocks were sectioned with a thickness of 4 µm using microtome and 
fixed on glass slides which were then used for various histological stainings.  
All animal procedures were conducted in accordance with the protocols 
approved by the Institutional Animal Care and Use Committee (33.9-42502-04-
14/1633; -17/2497 and -19/3085).  
 Metastatic incidence in transgenic mice 
For evaluation of micrometastases, three liver sections, each section separated 
by 20 µm, from each tumor-bearing caNfatc1;KrasG12D- and 
Ezh2fl/+;caNfatc1;KrasG12D mouse were stained for HA-NFATc1 for better 
visualization of tumor cells in the liver and were subsequently evaluated for 
metastasis. Mice that carried at least one HA-positive lesion which was 
surrounded by healthy liver tissue were considered as positive for metastasis.  
 
 Cell culture: 
 Cells, culture conditions and Tazemetostat (EPZ6438) treatment 
Primary PDAC cells derived from caNfatc1;KrasG12D (NKC) and 
KrasG12D;TP53R172H/+ (KPC) mice have been described previously (Baumgart et 
al. 2014; Hingorani et al. 2005). The isolation of pancreatic tumor and further 
generation of ENKC cell lines from tumor bearing Ezh2fl/+;caNFATc1;KrasG12D 
mice was performed by Waltraut Kopp. Primary murine PDAC cells were 
cultured using Dulbecco’s Modifies Eagle’s Medium (DMEM) containing 4.5 g/L 
D- Glucose, L-Glutamine supplemented with 10 % Fetal calf serum (FCS) and 
1 % Non-essential amino acids (NEAA). PANC-1 cells have been previously 
described (N. M. Chen et al. 2017) and were cultivated using DMEM containing 
4.5 g/L D-Glucose, L-Glutamine supplemented with 10 % FCS. PDX lines 
derived from the subcutaneous tumors of PDX mice were cultured in 
Keratinocyte-SFM (KSF):Roswell Park Memorial Institute (RPMI) (in 3:1 ratio) 
media supplemented with 2 % FCS, 1 % PenStrep, bovine pituitary extract and 
epidermal growth factor. Cells were grown in a sterile incubator with 5 % CO2 




reviving the cells for the experiments using the MycoAlert Mycoplasma 
Detection Kit from Lonza Group following the instructions mentioned in the kit.  
The cells grown up to 80 % confluency were utilized to make cell stocks for 
long term storage. Cells were trypsinized and centrifuged (1200 rpm for 3 
minutes) to pellet down the cells. The supernatant was discarded. Desired 
amount of cryoprotectant medium (90 % FCS + 10 % DMSO) was added onto 
the cells to attain a concentration of 2*106 cells/ml. Further 1 ml cell suspension 
was aliquoted into each cryovial and the cryovials were quickly transferred into 
frosty box (container containing isopropanol). The frosty box was left at -80 °C 
overnight and later transferred into liquid nitrogen for long term storage. While 
reviving the cells, cryovials were removed from the liquid nitrogen, quickly 
thawed in a waterbath (37 °C) and resuspended in a falcon containing 10 ml 
medium. The cell suspension was centrifuged and the supernatant containing 
freezing medium was discarded. Cells were resuspended in fresh medium and 
transferred into a cell culture flask. When passaging the cells, cells were briefly 
washed with PBS to remove the serum. Further, the cells were incubated with 
trypsin for 3-5 minutes and the reaction was neutralized by adding media on the 
cells. The content was collected in a falcon, centrifuged (1200 rpm for 3 
minutes) and the supernatant was discarded. The cells were then resuspended 
in fresh medium and split at the required density into a new cell culture flask. 
EZH2 methyltransferase inhibition was performed by treatment of indicated 
concentrations of Tazemetostat (EPZ6438) for 72 hours diluted in dimethyl 
sulfoxide (DMSO). Control cells were treated with equal amounts of DMSO. 
 Generation of EZH2 shRNA and CRISPR/Cas9 clones and transient 
transfection 
CRISPR/Cas9 based genome editing was utilized to generate EZH2 knockout 
PDAC cells. The PDAC cells were seeded into a 10 cm dish and once they 
attained 60 % confluency, they were transfected with pSpCas9(BB)-2A-Puro 
PX459 vectors containing single guide RNA (sgRNA) against murine or human 
EZH2, respectively, with the help of lipofectamine 2000. The following day, cells 
were split at different dilutions to allow the growth of single colonies and were 
treated with Puromycin (2 µg/ml) to select for transfected cells. Cells were 




Further, the single clones were picked by trypsinizing with small volume of 
trypsin, taking care not to disturb the neighbouring colonies. The cells were 
then transferred into 24-well plate and further expanded in culture. Some of 
these cells were used to harvest for lysate and tested on western blot for 
knockdown. Further, genomic DNA was isolated from those clones that showed 
EZH2 knockdown in western blot and a PCR was performed using the 
genotyping primers. The PCR products were then sequenced by Microsynth 
Seqlab GmbH to confirm the knockout. RNA and whole cell lysate (WCL) were 
also extracted to confirm the knockout at RNA and protein level. After 
confirmation of successful EZH2 knockout, cells were used for further 
experiments.  
For siRNA or shRNA based knockdowns, siLentFect or Lipofectamine 2000 
was used respectively. In short, the designated volume of siRNA and 
transfection reagent was added to OptiMEM and incubated for 20 minutes and 
subsequently added on the cells. Media was changed approximately 10 hours 
post transfection and cells were harvested for experiments after 48-72 hours. 
For EZH2 re-expression, HA-tagged EZH2 expression plasmid was transfected 
into NKC cells using lipofectamine 2000 and the transfected cells were selected 
using the antibiotic Hygromycin (300 µg/ml). The selected cells harboring 
transient re-expression of wildtype EZH2 were used for experiments. 
 
 Functional in vitro assays 
 Cell counting assay 
Cell counting assays were performed to determine the trend in cell growth. 
Experiments were conducted in triplicates. 2,500 cells were seeded in each 
well of a 6-well plate (Day 0). On day 3, cells were trypsinized and quantified 
before replating in a fresh 10 cm dish. Finally, on day 6, the cells were 
trypsinized and counted again. 
 BrdU (Bromodeoxyuridine) assay 
BrdU assays were performed to analyze the proliferation capacity of the cells 




cells were seeded into each well of a 96-well plate in five replicates per 
condition. After 72 hours, BrdU labelling reagent was added on the cells and 
incubated for 4 hours. Further steps were performed according to 
manufacturer’s instructions (BrdU cell proliferation kit, Roche, 11647229001). 
The absorbance was measured at 405 nm and the OD values were plotted as 
BrdU incorporation. 
 Boyden chamber assay 
Invasion capacities of PDAC cells were determined utilizing Boyden chamber 
assay. 50,000 cells were counted and seeded in 50 % matrigel into the 
collagen coated inserts. The inserts were placed into a 24-well plate. Complete 
media was added in the lower chamber and serum free media was added into 
the inserts. After 48 hours, the non-invaded cells and the matrigel were scraped 
off. The invaded cells were fixed with 4 % paraformaldehyde (PFA) for 20 
minutes, washed twice with 1X PBS, stained with DAPI (1:2000) and mounted 
on a glass slide. The DAPI positive nuclei were counted under fluorescence 
microscope. 
When evaluating the invasion potential of GATA6 knockdown cells, the cells 
transfected with siRNA against GATA6 were trypsinized 24 hours post 
transfection and seeded for Boyden chamber assay. 
 Colony formation assay 
Soft agar assays were performed to evaluate the ability of the cells for 
anchorage independent growth. The 6-well plates were coated with 1:1 mix of 
nobel agar (1 %) and culture medium. Further, 13,000 cells in medium were 
mixed with 1% nobel agar in the ratio 1:3 and seeded on these coated wells. 
After ensuring proper solidification of agar (approximately 30 minutes), cell 
culture medium was added on the top and 7 days later the colonies (cluster of 
cells visible under microscope) were counted under the microscope.  
 Sphere formation assay 
Sphere formation assays were conducted to analyze the stemness behavior of 
the cells. 30,000 cells were seeded into each well of a 6-well low attachment 




with 1X insulin, 0.4 % BSA, 20 ng/µl EGF, 10 ng/µl FGF, 2 % B27 supplement 
and N2 supplement). 0.02 ng/µl fibroblast growth factor (FGF) was added into 
each well every fourth day. After 11 days, pictures of the spheres from all the 
wells were taken using phase contrast microscopy. Total number of spheres in 
each well were counted, and the size of spheres were measured using ImageJ. 
The average value from three wells were used for plotting the graph. 
 
 Molecular biology 
 RNA isolation 
The media of cells was aspirated, and the cells were washed twice with 1X 
PBS. Further, cells were scraped in TRIzol and collected in a 1.5 ml eppendorf 
tube. 200 µl chloroform was added on the samples, vortexed and centrifuged at 
13500 rpm for 15 minutes at 4 °C. The aqueous phase was collected in a 
separate tube and RNA was precipitated by adding 500 µl isopropanol, allowing 
it to stand at room temperature (RT) for 15 minutes and centrifuging it at 13500 
rpm for 30 minutes at 4 °C. The RNA, which was pelleted down was then 
washed twice with 75 % ethanol, dried and resuspended in 30-40 µl aqua-dest 
water. RNA was stored at -80 °C. The concentration was measured 
photometrically using NanoPhotometer P-330 prior to cDNA synthesis or RNA 
sequencing. 
 cDNA synthesis 
1 µg of RNA was reverse transcribed into cDNA using iscript cDNA synthesis 
kit. cDNA synthesis was performed at 42 °C for 20 minutes and the enzyme 
was inactivated by heating the samples at 95 °C for 1 minute. The sample was 
further diluted in aqua dest water to 10 ng/µl.  
 Quantitative polymerase chain reaction (qPCR) 
qPCR was performed to quantify the gene expression. qPCR was performed in 
triplicates in a reaction volume of 10 µl. For each reaction, 1 µl of cDNA or DNA 
from ChIP was mixed with 3.9 µl H2O, 5 µl of SYBR green mix and 0.05 µl of 




Fast Optical 96-well reaction plate. The plate was sealed with an adhesive film 
and was briefly vortexed before placing it into StepOnePlus Real-Time PCR 
System. The PCR reaction was as follows: 
95 °C 10 minutes  
95 °C 15 second 
40 cycles 
60 °C 1 minute 
 
The CT values obtained were used to calculate the expression. The expression 
was normalized to the housekeeping gene Rplp0 and further normalized to 
control using the ΔΔCT method. For ChIP, qPCR samples were normalized 
corresponding to their ChIP input samples.  
 Chromatin Immunoprecipitation (ChIP) 
3.4.4.1 Cross linking and sonication 
Cells were grown in a 15 cm dish and were used for ChIP once they attained 
80 % confluency. Cells were fixed with 1 % formaldehyde in PBS for 20 
minutes and the reaction was quenched by adding 1.25 M glycine for 5 
minutes. Further, cells were washed twice with ice-cold PBS before adding 1 ml 
Nelson buffer containing protease inhibitors on the cells. The cells were 
scraped, collected in a 1.5 ml eppendorf tube and centrifuged at 11000 rpm, 4 
°C for 5 minutes. The nuclei which had formed a pellet were washed once more 
with 1 ml Nelson buffer. The final pellet was resuspended in 200 µl Gomes lysis 
buffer containing protease inhibitors and SDS, and then incubated on a rotating 
wheel at 4 °C for 15 minutes. The samples were sonicated using Biorupter with 
30 seconds ON/OFF pulse for 25 cycles. The sonicated samples were then 
centrifuged at 13000 rpm for 10 minutes at 4 °C and the supernatant was used 
to proceed with pre-clearing. 
3.4.4.2 Shearing check 
Shearing check was performed to confirm that the sonication has sheared the 
chromatin efficiently before proceeding with pre-clearing step. 10 µl of 
sonicated samples was incubated overnight on a shaker (65 °C, 800 rpm) in 




following day, 100 µl water, 10 µl LiCl (8 M) and 2 µl glycogen was added into 
the sample and DNA was isolated by adding phenol/chloroform/isoaymyl 
alcohol (200 µl) and centrifuging at full speed for 2 minutes. The aqueous 
phase was collected and the phenolic phase underwent back extraction with 
200 µl Tris (pH 8) 10 mM + 0.4 M LiCl followed by 2 minutes full speed 
centrifugation. The aqueous phase was added into the first tube and the DNA 
was precipitated using 100 % ethanol. The DNA pellet was washed once with 
70 % ethanol then finally resuspended in aqua-dest water with RNAse A (100 
µg/ml). Further, the DNA was mixed with loading dye and run on a 1.5 % 
agarose gel. The gel was observed under the gel documentation system and 
the shearing was considered efficient if most of the fragments were in the range 
200-500 bp. 
3.4.4.3 Pre-clearing and Immunoprecipitation 
Required volume of Agarose A beads was washed twice with Gomes lysis 
buffer. The ChIP samples were brought up to 500 µl in Gomes lysis buffer and 
were incubated with 100 µl Agarose A beads 50 % slurry for 1 hour at 4 °C. 
Afterwards, the sample were centrifuged and the supernatant was aliquoted for 
IP and one tube (2 % of the total sample) was saved as input. 
The chromatin aliquots were incubated with desired antibodies mix (1-2 µg/ IP) 
at 4 °C overnight on a cogwheel. On the following day, the blocked beads 
(Agarose A beads were blocked in Gomes lysis buffer with 1 mg/ml BSA 
overnight) were added and incubated for an hour. Further, the ChIP immune 
complex were washed once with Gomes lysis buffer, twice with Gomes wash 
buffer, twice with Gomes lysis buffer and finally with 1X TE buffer.  
3.4.4.4 DNA isolation 
The ChIP samples as well as input samples were diluted with 10 mM Tris (pH 
8) containing 10 µg RNAse A and incubated for 30 minutes at 37 °C. Further, 
50 µl Weinmann lysis buffer with an additional 30 µg proteinase K were added 
and incubated at 65 °C overnight. The samples were centrifuged and the 
supernatant was collected in a separate tube. The DNA on the beads was 
eluted by resuspending with 100 µl Tris (pH 8), incubating for 10 minutes at 65 




tube. The DNA was further extracted using the phenol/chloroform/isoaymyl 
alcohol extraction method (same as mentioned in shearing check). Finally, the 
DNA was resuspended in 40 µl aqua-dest water. qPCR was performed with the 
input and ChIP samples and further the expression was normalized to 
expression in input samples. 
 
 Protein biochemistry 
 Sample preparation and Bradford Assay 
For protein analyses, cells were harvested in whole cell lysis buffer 
supplemented with 1X cOmplete™ protease inhibitor cocktail and additional 
protease inhibitors- PMSF, NaF and NaO. Cells were scraped, collected in an 
eppendorf tube, incubated for 30 minutes on ice and centrifuged at 13000 rpm 
for 30 minutes at 4 °C. The  supernatant was collected in a fresh eppendorf 
tube which was stored at -20 °C for short time period and at -80 °C for long-
term storage. Protein concentration was measured using Bradford reagent 
following standard protocol. Different dilutions of Bovine serum albumin (BSA) 
was used as the standard. The absorbance of the standards and samples were 
measured at 595 nm. The absorbance value of the standards were plotted and 
the coefficent was derived which was used to calculate the concentration of the 
sample. 
 SDS PAGE and Western blot analysis 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed to separate the proteins based on their molecular weight. We used a 
10 % gel to detect proteins of size larger than 30 kDa and a 15 % gel to 
visualize proteins smaller than 30 kDa. To generate the polyacrylamide gels, 
the plates were assembled together in the cassette. Approximately 4.5 ml 
resolving gel solution was poured in the spacer within two plates and was 
overlayed with stacking gel solution. 10 well comb was placed and the gel was 
allowed to solidify for 30-45 minutes. Further the comb was carefully removed, 
gel was placed in the electrophoresis tank and the tank was filled with running 




°C for 5 minutes. These samples were loaded into the wells of the gel and the 
electrophoresis was performed at 120 volts for approximately 1 hour. Once the 
proteins were separated by polyacrylamide gel electrophoresis (PAGE), the 
proteins on the gel were transferred onto a nitrocellulose membrane using a 
TurboBlot system (fixed: 25 V and 1.0 A, time: 22 minutes for 10 % gels and 10 
minutes for 15 % gels). Further, the membrane was briefly stained with 
Ponceau S solution to visualize the proteins bands thereby to confirm the 
blotting. The membrane was blocked using 5 % milk in TBST and incubated 
with primary antibodies overnight at 4 °C. Membranes were then incubated with 
respective secondary antibodies for 1 hour at room temperature. Bands were 
visualized in Intas ECL Chemocam Imager using chemiluminescence. 
 
 Next generation sequencing: 
 ChIP seq library preparation and analysis 
For ChIP-seq, ChIP was performed as described above and with antibodies 
against EZH2, H3K27me3 and H3K4me3. IgG was used as a control. 
Subsequently, DNA samples were sonicated in a Biorupter® Pico to obtain 
approximately 300 bp fragments which were used for library preparation with 
the MicroPlex Library Preparation Kit as per manufacturer’s protocol. 
Sequencing was performed using the HiSeq 2000 Illumina platform of the NIG. 
Subsequently, the ChIP-seq files were analyzed in the public server 
(usegalaxy.org). The quality of the raw files were assessed by running FASTQ 
quality check (FASTQC). After ensuring the quality of the raw data, the 
sequence reads were aligned to the mouse reference genome (mm9) using 
Bowtie2 (version 0.4) with default parameters (Langmead and Salzberg 2012) 
and the aligned reads were saved as a BAM file. This file was used for peak 
calling utilizing the Model based Analysis of ChIP-seq (MACS2 version 
2.1.0.20151222) tool (Zhang et al. 2008) on UseGalaxy (usegalaxy.org) server. 
The cut off value for peak detection was set to 0.05. BigWig files were 
generated using BamCoverage (version 2.2.3) from deeptools (Ramírez et al. 
2016) and were visualized using integrative genomics viewer (IGV version 
2.5.3) (Robinson et al. 2011). Further, BigWig and bed files were used to 




using CEAS tool (Shin et al. 2009) on Galaxy cistrome. Differential binding 
analysis was performed to identify differentially occupied regions in shRNA 
EZH2- compared to shRNA control NKC cells using the Bioconductor R 
package Diffbind (Ross-Innes et al. 2012) run on R version 3.6.1 according to 
the instruction manual. Furthermore, Genomic Regions Enrichment of 
Annotations Tool (GREAT) analysis (Mclean et al. 2010) was used to identify 
associated genes with regions identified by Diffbind analysis. The default 
association rule, basal plus extension (5 kb upstream, 1kb downstream plus 
distal 1Mb), was set for GREAT analysis. Further, principle component analysis 
(PCA) for the H3K27me3 and H3K4me3 profiles was plotted in R. Heatmaps 
and average profiles for occupancy were generated using the computeMatrix 
and plotHeatmap tools on the UseGalaxy server and peak center was set as 
the reference point mode.  
For analyses in PANC-1 cells, input and EZH2 ChIP-seq sequence reads were 
aligned against the human reference genome (hg38) and BigWig files were 
generated as described above. The input peaks were subtracted from the 
EZH2 binding peaks and visualized in IGV. 
 RNA seq library preparation and analysis 
ShRNA control and shRNA EZH2 NKC cells were cultured in triplicates and 
later harvested in TRIzol. RNA was isolated by phenol-chloroform method 
followed by confirming the purity and integrity on 1 % agarose gel. 500 ng of 
total RNA was used to prepare libraries using True seq RNA library preparation 
kit as per the manufacturer’s instructions. cDNA library concentrations and 
fragment sizes were controlled by Qubit and bioanalyzer respectively prior to 
sequencing in the NGS Integrative Genomics Core Unit (NIG) of the UMG. The 
FastQ files from the RNA sequencing were analyzed in the public server 
usegalaxy.org. The reads were aligned to the murine transcriptome mm9 using 
TopHat2 (version 2.1.0) (D. Kim et al. 2013). Further, differential gene 
regulation and Fragment Per Kilobase Million (FPKM) values were obtained by 
Cuffdiff (version 2.2.1) and Cuffnorm (version 2.2.1.1) respectively (Trapnell et 
al. 2013). The read counts obtained by HTSeq (version 0.9.1) (Anders, Pyl, and 
Huber 2015) were used to plot Principal Component Analysis (PCA) in R. 




background signals. Gene ontology was performed using PANTHER GO 
Ontology database (Binomial test with Bonferroni correction) and pathways with 
FDR < 0.05 were considered as significant pathways. GSEA was performed 
using standard parameters (Signal2Noise metric for gene ranking).  
 
 H&E staining and immunohistochemistry 
Upon sacrificing the mice, pancreas and liver tissue were collected in 
parafolmaldehyde, dehydrated in increasing concentrations of ethanol and 
further embedded in paraffin to make tissue blocks. Paraffin blocks were 
sectioned into 4 µm sections and fixed on glass slides. Hematoxylin & Eosin 
(H&E) stainings were performed to visualize the tissue morphology. To this end 
the slides were placed in roticlear to remove the paraffin (de-waxing). Further, 
the tissue sections were hydrated by placing the slides in decreasing 
concentrations of ethanol (99 %, 96 %, 80 %, 70 %, 50 %). The slides were 
placed in hematoxylin solution, which stains the nuclei blue, for approximately 5 
minutes and then rinsed with tap water for 7 minutes. Further, the slides were 
transferred to the eosin in 0.2 % acetic acid solution, which consists of a dye 
that stains the cytoplasm, for approximately 10 seconds. The sections were 
further dehydrated by placing in increasing concentrations of ethanol (70 %, 80 
%, 96 %, 99 %) and finally in roticlear. The slides were mounted using a cover 
slip and with a mounting solution  and further viewed under the microscope. 
For immunohistochemistry (IHC), the sections were de-waxed by placing the 
slides in roticlear and further hydrated by placing in decreasing concentrations 
of ethanol. Then, the slides were covered with TE/citrate buffer and boiled for 5-
10 minutes in the microwave to expose the antigens and then cooled down by 
placing it on the ice. Further the sections were incubated in 3 % hydrogen 
peroxide solution for 10 minutes to block the endogenous peroxidase activity. 
The slides were placed in the cadenxa slide holding system and then blocked 
with 10 % BSA solution prepares in PBST (containing 1 % Tween or 1 % 
TritonX). The slides were then incubated overnight with the primary antibody. 
The following day, slides were washed twice with PBST and incubated with the 
secondary antibody for 1 hour, followed by incubating with AB complex for 




ABC kits). The slides were then washed with PBST and stained with DAB 
solution. The reaction was stopped by placing the slides in water and further 
the slides were counterstained in hematoxylin for 5 minutes. Slides were placed 
under tap water for 7 minutes for the nuclei stain to develop into blue colour. 
Finally, sections were dehydrated and mounted as explained for H&E stainings. 
The slides were viewed under the microscope. 
 
 Tissue Microarray Analysis (TMA) in human PDAC samples 
EZH2 and GATA6 stainings in TMA were provided by the Institute of Pathology, 
UMG, Göttingen. TMAs were prepared from 54 resected PDAC patients with 
three to four cores per patient. TMAs were evaluated for nuclear EZH2 and 
GATA6 expression and were scored in accordance to the Immune Reactive 
Sore (IRS). Each tissue was given a score for the percentage of positively 
stained cells (A) and intensity of staining (B). Multiplying the scores of two 
variables (A*B) gave a IRS ranging from 0 to 12. Tissues with IRS ≤ 3 were 
considered as tissues with null or mild staining and the tissues with IRS > 3 
were considered as moderate or strongly stained. 
 
 Statistical analysis 
Statistical analysis was performed by Graphpad Prism (version 6.0). Data are 
represented as mean ± standard deviation (SD). Fisher's exact test was used 
to analyze the significance of in vivo data. Log-Rank test was used for the 
survival analysis. Two-tailed unpaired student’s t-test, one-way and two-way 
ANOVA were used calculate the statistical significance of in vitro data 
(described in each figure legend). p value of < 0.05 was considered as 
statistically significant. p- values < 0.05, < 0.01 and < 0.001 are depicted as *, 









 EZH2 in tumor progression  
 EZH2 is overexpressed in dedifferentiated human PDAC 
In order to elucidate the role of EZH2 in PDAC, we initially examined EZH2 
expression in human PDAC samples and adjacent normal pancreatic tissue. To 
this end we conducted EZH2 IHC in a Tissue Microarray (TMA) of resected 
PDAC samples from 54 patients. Consistent with previous reports (Ougolkov, 
Bilim, and Billadeau 2008), EZH2 was almost absent in the normal pancreas 
whereas its expression increased in the epithelial part of PDAC tissues (Figure 
5A).  
Next, we used the immunoreactive score (IRS) to correlate EZH2 expression 
with the tumor grading information of the respective donor patient as provided 
by the Institute of Pathology. The IRS scoring system considers the percentage 
of positively stained cells and the intensity of the staining (Fedchenko and 
Reifenrath 2014). A significant number of patients with low EZH2 levels 
possessed low grade pancreatic tumors. Overall, there was a significant 
association between high EZH2 levels with high-grade tumors (Figure 5B). 
Together, these analyses suggest overexpression of EZH2 in PDAC vs normal 










Figure 5: EZH2 expression correlates with high grade PDAC. 
(A) Representative immunohistochemical analysis of EZH2 expression in healthy 
pancreatic tissue, moderately and poorly differentiated PDAC from a TMA performed 
in human PDAC patients (n = 54 patients). Magnification 100X, Scale bar: 100 µm. (B) 
Correlation of EZH2 expression (IRS score) and tumor grading in the same TMA. Each 
dot represents a patient. Values represent mean ± SD. Significance was determined 
by two-tailed unpaired student’s t-test. 
 
 
 EZH2 drives PDAC progression in transgenic mice 
Given the observations in human PDAC tissues, we sought to dissect the 
functional implications of EZH2 in vivo using transgenic mouse models. We 
utilized the caNfatc1;KrasG12D (NKC) mice which have been previously 
described (Baumgart et al. 2014). Briefly, this transgenic mouse model has the 
gatekeeper KrasG12D mutation and constitutive expression of HA-tagged 
NFATc1 in the pancreas. NFATc1 is a well-studied inflammatory transcription 
factor and in combination with KrasG12D gives rise to PDAC with a penetrance 




mimics human PDAC with frequent occurrence of liver metastasis, ascites and 
bile obstruction (Baumgart et al. 2014).  
To investigate the impact of EZH2 expression in this mouse model, 
caNfatc1;KrasG12D mice were crossed with Ezh2fl/fl mice to obtain 
Ezh2fl/fl;caNfatc1;KrasG12D littermates. Surprisingly, homozygous 
Ezh2fl/fl;caNfatc1;KrasG12D animals died 5-10 days postnatally. Necropsy of 
mice showed signs of liver inflammation, severe pancreatic atrophy or complete 
loss of the pancreatic organ (Figure 6), indicating that in the context of 
constitutively active NFATc1, EZH2 is vital for the development of a 





Figure 6: Complete loss of EZH2 hampers pancreatic development in mice. 
H&E staining in pancreatic tissue of Ezh2fl/fl;caNfatc1;KrasG12D and 
Ezh2fl/+;caNfatc1;KrasG12D mice displaying severe pancreatic atrophy and liver 
inflammation in animals with homozygous Ezh2 depletion. Magnification 100X, Scale 









As the homozygous Ezh2 knockout mice could not be used for the study, we 
interbred Ezh2fl/fl;caNfatc1;KrasG12D mice with Ezh2+l+ (wildtype) animals to 
obtain Ezh2fl/+;caNfatc1;KrasG12D mice with heterozygous EZH2 expression. 
Both caNfatc1;KrasG12D and Ezh2fl/+;caNfatc1;KrasG12D (ENKC) mice gave rise 
to all steps of pancreatic carcinogenesis. ADM and PanIN lesions were 
observed in caNfatc1;KrasG12D mice as soon as 2 weeks after birth. While most 
of the 8 week old mice displayed the full PanIN PDAC precursor lesions, nearly 
all 7 month old animals suffered from PDAC. The pancreas of 8 week old 
Ezh2fl/+;caNfatc1;KrasG12D animals displayed ADMs and PanIN precursor 
lesions and few of these mice developed PDAC. 
The ADM, PanIN lesions and PDAC of caNfatc1;KrasG12D and 
Ezh2fl/+;caNfatc1;KrasG12D mice were subjected to various 
immunohistochemical analyses. As this mouse model has overexpression of 
HA-tagged NFATc1, tissues were stained for HA-tag thereby validating the 
expression of NFATc1 and to distinguish epithelial- from non-epithelial tissue 
parts. Consistent with the observations in human pancreatic cancer tissues, 
EZH2 was nearly absent in acinar cells but showed increased expression and 
activity (as illustrated by H3K27me3 staining) in PDAC precursor lesions and 
established tumors. Interestingly, PDAC developing in 
Ezh2fl/+;caNfatc1;KrasG12D mice were overall more differentiated than the 
tumors in caNfatc1;KrasG12D mice (Figure 7), suggesting that EZH2 promotes 





Figure 7: EZH2 drives PDAC development and dedifferentiation. 
Representative images of H&E and other immunohistochemical stainings (HA-
NFATc1, EZH2, H3K27me3) in ADM, PanIN lesions and PDAC of caNfatc1;KrasG12D 






Mice were followed till the end point criteria were reached and then sacrificed. 
The end point was defined as mice experiencing weight loss of more than 20 % 
or showing signs of pain. The pancreas tissue of the mice was stained with 
H&E and was evaluated by a pathologist to determine which tissue contains 
PDAC. Remarkably, caNfatc1;KrasG12D mice developed PDAC with almost 100 
% incidence whereas only 5 out of 25 Ezh2fll+;caNfatc1;KrasG12D mice (20 %) 
developed PDAC (Figure 8A). Furthermore, Kaplan Meier plot was plotted to 
compare the survival between the two groups of mice. Surprisingly, and despite 
the EZH2-status dependent differences in PDAC development, 
Ezh2fl/+;caNfatc1;KrasG12D (ENKC) mice had a median survival of 165 days 
which was comparable to that of caNfatc1;KrasG12D mice, which displayed a 
median survival of 145 days (Figure 8B). Ezh2fl/+;caNfatc1;KrasG12D mice 
displayed initial signs of pancreatic insufficiency and atrophy at an advanced 
age, potentially explaining the insignificant differences seen in the survival of 




Figure 8: EZH2 correlates with increased PDAC incidence in transgenic mice 
(A) Bar graph showing PDAC incidence in survival mice of indicated genotypes. 25 
mice per genotype were enrolled into the study. Significance was determined by two-
tailed Fisher’s exact test (B) Kaplan-Meier plot displaying survival of 
Ezh2fl/+;caNfatc1;KrasG12D (ENKC) mice (median survival 162 days) compared to that 
of caNfatc1;KrasG12D (NKC) mice (median survival 145 days). Significance was 





 EZH2 drives liver metastasis in transgenic mice 
Tumor dedifferentiation is associated with invasion and metastasis. The liver is 
the most common site for distant metastasis in pancreatic cancer patients 
(Yachida and Lacobuzio-Donahue 2009). Therefore, tumor-bearing mice from 
both genotypes were evaluated for liver metastasis. Three liver sections from 
each tumor-bearing mouse from both groups were stained for HA-NFATc1 for 
better visualization of PDAC cells in the liver. Mice that carried at least one HA-
positive lesion in the liver which was surrounded by healthy liver tissue were 
considered positive for metastasis. While 33 % of tumor-bearing 
caNfatc1;KrasG12D mice displayed liver metastasis, only 20 % of 
Ezh2fl/+;caNfatc1;KrasG12D mice developed metastasis (Figure 9). This suggests 
a possible role of EZH2 in promoting metastasis.  
 
Figure 9: EZH2 deficiency reduces metastatic incidence. 
(A) Representative images of H&E and HA-NFATc1 staining in liver sections of 
caNfatc1;KrasG12D (NKC) and Ezh2fl/+;caNfatc1;KrasG12D (ENKC) mice. Magnification 
100X, Scale bar 100 µm. (B) Bar graph showing percentage of tumor bearing mice 
from indicated genotypes carrying liver metastasis. Significance was determined by 




Together, these results in human PDAC samples and transgenic mouse 
models suggest a critical involvement of EZH2 in driving tumor progression and 
dedifferentiation towards a highly aggressive PDAC phenotype. 
 
 Functional implications of EZH2 in PDAC cells 
To delineate the functional implications of EZH2 in PDAC maintenance, we 
isolated pancreatic tumors from the EZH2-expressing caNfatc1;KrasG12D mice 
and further harvested primary PDAC cells (NKC cells) from the tumor 
(Baumgart et al. 2014). NKC cells were subjected to shRNA mediated 
knockdown of EZH2 to generate stable EZH2 knockdown NKC cells (Figure 
10A). The western blot confirms the reduction in EZH2 expression and 
subsequent decrease in H3K27me3 levels upon EZH2 knockdown (Figure 
10B). The shRNA control and shRNA EZH2 NKC cells were utilized to perform 







Figure 10: Generation of shRNA-mediated stable knockdown of EZH2 in NKC 
cells. 
(A) Schematic displaying the isolation of primary PDAC cells (NKC cells) from 
caNfatc1;KrasG12D (NKC) mice and further generation of shRNA-mediated stable 
knockdown of EZH2 in these cells. (B) Western blot depicting reduced EZH2 and 
H3K27me3 expression in NKC cells upon stable shRNA-mediated EZH2 depletion. H3 






 EZH2 depletion reduces proliferation in NKC cells 
Uncontrolled cell proliferation is an important property of cancer cells (Hanahan 
and Weinberg 2011) and previous studies have investigated the involvement of 
EZH2 in mediating cellular proliferation (Ougolkov, Bilim, and Billadeau 2008). 
Therefore, we decided to analyze the consequences of EZH2 depletion in NKC 
cells on tumor cell proliferation. Cell counting assay is a very simple method to 
evaluate cell growth kinetics. 2500 cells were seeded on day 0 and the number 
of cells was counted subsequently on day 3 and day 6. On the 6th day, there 
was a significantly higher number of shRNA control cells than shRNA EZH2 
cells (Figure 11A), suggesting that cells grow slower upon depletion of EZH2. 
Bromodeoxyuridine (BrdU) assay is a widely preferred, efficient method to 
detect the proliferation of cells. BrdU is a synthetic analog of thymidine and 
when added on cells gets incorporated into the DNA of replicating cells. The 
shRNA EZH2 cells displayed lower levels of BrdU incorporation, providing 
evidence that PDAC cell proliferation reduces significantly upon EZH2 depletion 
(Figure 11 B). 
 
 
Figure 11: EZH2 depletion reduces cell proliferation in NKC cells. 
(A) Graph from cell counting assay depicting the number of cells counted on days 0, 3 
and 6 in the indicated cells. (B) Bar graph from BrdU cell proliferation assay showing 
BrdU incorporation in NKC cells in the presence and absence of EZH2. Values 
represent mean ± SD from 3 independent experiments. Significance was determined 





 EZH2 depletion reduces stemness properties in NKC cells 
Another important property of cancer cells is anchorage independent growth 
(Hanahan and Weinberg 2011) which can be assessed in vitro by colony 
formation (also known as soft agar assay) assay. This assay evaluates the 
ability of high proliferating tumor cells to form colonies on the soft agar plate 
(Borowicz et al. 2014). Our study showed that EZH2 depleted NKC cells have 
reduced capacity to form colonies on the soft agar compared to the control cells 
(Figure 12A) confirming that EZH2 deficiency diminishes anchorage-
independent growth in NKC cells. 
Stemness appears to be a fundamental hallmark of malignancy and tumor cell 
plasticity (Lathia and Liu 2017). Sphere formation assay is a general in vitro 
approach to analyze the stemness feature of the cells based on their ability to 
form spheres when allowed to grow in suspension in a serum-free sphere 
medium (H. Wang, Paczulla, and Lengerke 2015). In our study, shRNA EZH2 
cells formed an overall less number of spheres and relatively smaller spheres 
compared to the shRNA control cells (Figure 12B), confirming that in the 
absence of EZH2, NKC cells reduce their stemness potential.  
 
 
Figure 12: EZH2 deficiency reduces anchorage independent growth and 
stemness in NKC cells 
(A) Bar graph displaying the number of colonies formed in the soft agar in NKC cells in 
the presence and absence of EZH2. Values represent mean ± SD from 3 independent 
experiments. Significance was determined by two-tailed unpaired student’s t-test. (B) 
Bar graph illustrating total number and size of spheres in the same cells. Values 




 EZH2 depletion reduces the invasive potential of NKC cells 
Cell invasion is the ability of cancer cells to penetrate through the extracellular 
matrix which is basically the primary step in the process of metastasis 
(Zeeshan and Mutahir 2017). Our in vivo data suggests a reduced metastatic 
potential upon heterozygous Ezh2 depletion (Figure 9). Based on these 
findings, we performed a Boyden chamber assay which is a commonly used in 
vitro method to assess tumor cell invasion. The Boyden chamber based 
invasion assay displayed that upon knockdown of EZH2, there is a reduction in 
the capacity of NKC cells to invade (Figure 13).  
 
 
Figure 13: EZH2 knockdown reduces invasive capacity of NKC cells. 
(A) Representative image of DAPI stained nuclei demonstrating invaded NKC cells 
from indicated conditions. (B) Bar graph displaying quantification of invaded cells from 
Boyden chamber assay shown in A. Values represent mean ± SD from 3 independent 
experiments. Significance was determined by two-tailed unpaired student’s t-test. 
 
 
Taken together, all the above-mentioned functional assays in PDAC cells 
indicate that  loss of EZH2 significantly diminishes proliferation, anchorage 
independent growth, stemness and invasive capacity, indicating that EZH2 
depletion strongly reduces cellular plasticity and the tumor promoting potential 






 Mechanistic role of EZH2 in PDAC 
In order to understand the mechanism through which EZH2 mediates regulation 
of pancreatic plasticity and dedifferentiation, we set up next-generation 
sequencing approaches in shRNA control and shRNA EZH2 NKC cells. RNA-
seq was performed to determine differential gene regulation by EZH2 and 
Chromatin Immunoprecipitation followed by parallel deep sequencing (ChIP-
seq) identifies the genes directly bound by the methyltransferase (Figure 14). 
The intersection of information from both assays enables us to identify EZH2-





Figure 14: Schematic of the sequencing analysis. 
Ovelapping the genes derived from high-throughput ChIP- and RNA- sequencing 







 EZH2 regulates genes mediating differentiation and tumor 
progression in PDAC 
ShRNA control and shRNA EZH2 NKC cells were seeded in triplicates and 
were subjected to high throughput RNA-seq. Before proceeding with the 
analysis, we verified the quality of the reads and performed Principal 
component analysis (PCA) through which we confirmed the similarity between 
the triplicates of each condition and the differences between the two conditions 
(Figure 15A). For further analyses, genes with a Fragments Per Kilobase of 
transcript per Million mapped reads (FPKM) threshold less than 0.2 were 
eliminated to reduce false positive expressions, which eliminated approximately 
50 % of the genes and kept 13,467 genes for downstream analysis. 
In order to investigate the pathways affected by EZH2 depletion, we performed 
Gene set enrichment analysis (GSEA) in control and EZH2 knockdown 
samples. GSEA is a tool that determines if a predefined gene set coding for a 
particular pathway is significantly enriched in the given sample (Subramanian et 
al. 2005). We used the default curated gene sets and examined significantly 
enriched pathways. While gene signatures related to tumor cell proliferation, 
migration and metastasis were enriched in shRNA control cells, pathways 
related to differentiation and apoptosis were enriched upon EZH2 depletion 
(Figure 15B). In summary, GSEA results strengthened our hypothesis that 








Figure 15: EZH2 deficiency leads to enrichment of pathways related to PDAC 
progression. 
(A) PCA plots from RNA-seq analyses showing the triplicates of shRNA control and 
shRNA EZH2 clusters. (B) Gene set enrichment analysis (GSEA) performed from 
RNA-seq analysis displaying pathways positively (blue) and negatively (red) enriched 
in shRNA EZH2 cells. Significance was determined based on normalized enrichment 




 EZH2 depletion leads to enrichment of favorable prognosis and 
differentiation gene sets 
To investigate if EZH2 has any prognostic relevance, we utilized the 
transcriptomics data from 176 pancreatic cancer patients available in The 




classified as unfavorable prognosis genes and 857 genes were identified as 
favorable prognosis genes in PDAC (Cancer Genome Atlas Research Network 
et al. 2013). High expression of favorable genes at diagnosis indicated better 
overall survival whereas increased expression of unfavorable genes indicated 
lower survival of PDAC patients. We performed GSEA on our genome-wide 
expression data using these prognostic gene sets. There was a positive 
enrichment of genes associated with favorable prognosis in the context of 





Figure 16: EZH2 depletion mediates better prognosis and cell differentiation 
programs. 
GSEA performed from RNA-seq analysis illustrating enrichment of (A) PDAC favorable 
prognosis gene set (B) cell differentiation gene set and (C) stem cell differentiation 







Our findings accomplished in in vivo models and functional assays link EZH2 to 
PDAC dedifferentiation. In order to explore if EZH2 regulates gene signatures 
related to differentiation programs, we performed GSEA using cell- and stem 
cell- differentiation gene sets. In accordance with our findings in transgenic 
mice and PDAC cells, we observed an induction of gene signatures associated 
with cellular differentiation upon EZH2 depletion (Figure 16 B&C). These 
observations argue that EZH2 regulates PDAC plasticity by repressing 
programs required to maintain a differentiated state.  
 
 Classical subtype PDAC genes are positively enriched upon EZH2 
depletion  
So far, our data suggest that EZH2 activity is associated with an aggressive 
PDAC phenotype, dedifferentiation and an unfavorable prognosis. As these 
features also characterize certain PDAC subtypes (Collisson et al. 2011; Moffitt 
et al. 2015), we asked whether EZH2 controls gene signatures associated with 
a particular molecular PDAC subtype. Two extreme molecular PDAC subtypes 
have remained consistent in all the studies – the classical and basal-like 
subtype (P. Bailey et al. 2016; Collisson et al. 2011; Maurer et al. 2019; Moffitt 
et al. 2015; Puleo et al. 2018). 
In one of the latest works with regard to PDAC subtypes performed by Puleo et 
al., they considered all previous subtyping studies and defined two important 
PDAC subtypes in the epithelial compartment of the tumor – pure classical and 
basal-like subtypes (Puleo et al. 2018). While the basal-like subtype exhibits 
higher tumor grade and poor survival, the pure classical subtype is associated 
with a more differentiated phenotype and exhibits a better prognosis. To 
evaluate if EZH2 is involved in the regulation of gene signatures defining pure 
classical vs basal-like subtypes, we intersected our RNA-seq data with Puleo et 
al. defined gene sets. Interestingly, we found a positive enrichment of pure 
classical gene signatures and negative enrichment of basal-like gene 






Figure 17: EZH2 knockdown leads to positive enrichment of classical PDAC- and  
negative enrichment of basal-like PDAC subtype gene signatures. 
Analysis of RNA-seq (A) GSEA plot and (B) Heatmap illustrating positive enrichment 
of Pure classical gene signatures (Puleo et al. 2018) upon EZH2 knockdown. (C) 
GSEA plot and (D) Heatmap illustrating negative enrichment of basal-like gene 
signatures (Puleo et al. 2018) upon EZH2 knockdown. Significance was determined 





Importantly, molecular PDAC subtypes not only display distinct histological 
features and prognostic implications, they also exhibit diverse metabolic 
profiles. Indeed, Daemen et al. have identified two extreme metabolic profiles 
which strongly associate with the classical and basal-like subtypes (Daemen et 
al. 2015). While the lipogenic subtype that consists of genes associated with 
lipogenesis is strongly associated with classical PDAC, the glycolytic subtype 
which comprises genes involved in glycolysis correlates with basal PDAC gene 
signatures (Daemen et al. 2015). In line with the aforementioned enrichment of 
classical gene signatures in shEZH2 cells, GSEA using these metabolic gene 
sets revealed that lipogenic gene signatures are enriched in the context of 
EZH2 deficiency (Figure 18). This data further strengthens the observation that 




Figure 18: EZH2 knockdown leads to enrichment of lipogenic subtype gene 
signatures. 
Analysis of RNA-seq: GSEA plot depicting enrichment of lipogenic gene signatures in 
shRNA EZH2 condition. Significance was determined based on NES and FDR q value. 
 
 
 EZH2 binds largely on TSS/promoter sites of its target genes  
The transcriptomics data supported the hypothesis that EZH2 regulates 
differentiation-associated gene signatures and pathways. To further elucidate 
the mechanistic background of oncogenic EZH2 activity in PDAC and to identify 
target genes directly bound by EZH2, we performed genome-wide binding 




were seeded in triplicates and subjected to ChIP-seq. ChIP-seq with an 
antibody recognizing EZH2 was performed in shRNA control cells to identify the 
genes occupied by EZH2. Firstly, we analyzed the location on the genome 
where EZH2 majorly binds. We assessed the enrichment of EZH2 binding at 
different genomic regions like promoter, introns, exon etc. using Cis-regulatory 
Element Annotation System (CEAS). CEAS is a tool that enables the 
visualization of relative ChIP enrichment at important genomic locations 
compared to the whole genome (Shin et al. 2009). The CEAS analysis of EZH2 
ChIP-seq revealed that most of the EZH2 binding regions were confined to the 
TSS/Promoter of the genes (17.1 %) compared to whole-genome (1.1 %) 
(Figure 19A). Additionally, GREAT analysis also validated the genome-wide 







Figure 19: EZH2 largely occupies the promoter region of its target genes. 
(A) Cis-regulatory Element Annotation System (CEAS) analysis of EZH2 ChIP-seq 
showing relative enrichment of EZH2 on promoters and gene bodies compared to the 
whole genome. (B) Genomic Regions Enrichment of Annotations Tool (GREAT) 




 EZH2-deficiency fosters a shift in histone modifications at EZH2 
target genes  
To study EZH2-dependent histone modifications, EZH2 ChIP-seq was 
accompanied by ChIP-seq analysis for H3K27me3 and H3K4me3 in the 
presence and absence of EZH2. Principal component analysis (PCA) in 




triplicates of each condition and the differences between the two conditions 




Figure 20: PCA plots of histone marks from ChIP sequencing analysis 
PCA plots from ChIP-seq analysis of (A) H3K27me3 and (B) H3K4me3 illustrating 
distinct clusters of shRNA control and shRNA EZH2 triplicates. 
 
Subsequently, we developed heatmaps to study the general trends in genome-
wide EZH2 binding and subsequent enrichment of histone modifications. Figure 
21A displays the heatmap profile of EZH2 binding on the shRNA control 
genome. Consistent with its function as a transcriptional repressor, EZH2-
bound regions were enriched for the repressive H3K27me3 mark, which was 
decreased in EZH2 knockdown cells (Figure 21B). In contrast, H3K4me3, 
which is a transcriptionally active mark (Hemming et al. 2016; P. Wang et al. 








Figure 21: Loss of EZH2 binding leads to decrease in H3K27me3 and increase in 
H3K4me3 enrichment. 
Heatmaps from ChIP-seq data in NKC cells depicting (A) EZH2 binding on the 
genome. (B) H3K27me3 occupancy and (C) H3K4me3 occupancy on EZH2 bound 
regions in indicated conditions. 
 
 EZH2 targets differentiation-associated genes   
In order to identify direct EZH2 targets genes, we combined the output of our 
ChIP- and RNA-seq data. With the ChIP-seq data, we performed differential 
binding (Diffbind) analysis to identify differentially occupied regions in shRNA 
EZH2 compared to shRNA control NKC cells. Furthermore, we performed 
Genomic Regions Enrichment of Annotations Tool (GREAT) analysis to identify 
genes associated with regions identified by Diffbind analysis.  
To obtain direct EZH2 binding targets, we focused on genes that i) showed 
EZH2 binding on shRNA control samples, ii) significantly lost H3K27me3 
enrichment (log2FC > 2, q < 0.1) and iii) gained H3K4me3 occupancy (log2FC 
> 0.5, q < 0.1) upon EZH2 knockdown. This strategy led to the identification of 
965 target genes (Figure 22A) which are bound and potentially repressed by 
the histone methyltransferase. We additionally  performed CRISPR/Cas9 
mediated knockout of EZH2 in NKC cells (shown in appendix, figure 35) and 
further subjected CRISPR/Cas9 control vs CRISPR/Cas9 EZH2 NKC cells to 




genes identified by ChIP-seq were intersected with genes that were found to be 
upregulated upon shRNA- (log2FC > 0.5, q < 0.1) and CRISPR/Cas9 (log2FC > 
0.5, q < 0.1) mediated depletion of EZH2 in the RNA-seq. We identified 47 final 
direct target genes (Figure 22B), whose TSS region is bound  by EZH2 and 
meanwhile expression is increased in the context of EZH2 depletion. 
Consistent with our observations in phenotypic and functional data, Gene 
ontology (GO) analysis of these 47 genes revealed pathways related to 
development and differentiation (Figure 22C).  
 
 
Figure 22: Direct target genes of EZH2 mediate developmental and cell 
differentiation related programs. 
(A) Venn diagram showing the intersection of genes fulfilling the following criteria: 
bound by EZH2, decreased H3K27me3 enrichment in shRNA EZH2 samples (log2FC 
> 2, q < 0.1) and increased H3K4me3 enrichment in shRNA EZH2 samples (log2FC > 
0.5, q < 0.1) as identified by ChIP-seq. (B) Venn diagram showing intersection of direct 
EZH2 target genes from A with genes upregulated upon shRNA- (log2FC > 0.5, q < 
0.1) and CRISPR/Cas9- (log2FC > 0.5, q < 0.1) mediated EZH2 depletion. Box 
indicates an excerpt of the final 47 target genes. (C) GO gene enrichment analysis 





Out of the 47 direct EZH2 targets we selected a set of eleven genes with 
potential implication in PDAC biology. The ChIP-seq based binding profiles 
were viewed using an integrated genome viewer (IGV), which is a widely used 
visualization tool for NGS data (Robinson et al. 2011; Thorvaldsdóttir, 
Robinson, and Mesirov 2013). The IGV profile of 11 selected EZH2 target 
genes depicted in figure 23 displays the EZH2 binding and associated changes 
in occupancy of histone marks on TSS of the genes in the presence and 
absence of EZH2.  
 
Figure 23: IGV profile of selected 11 EZH2 direct target genes. 
11 genes with potential implications in PDAC were selected from the 47 direct EZH2 
target genes. The figure depicts the Integrated genome viewer (IGV) profiles of the 
finally selected 11 EZH2 target genes. 
 
 EZH2 target gene expression validation 
The selected EZH2 target genes were further validated in independent 
experiments. We performed expression analysis of these target genes in 
shRNA control vs shRNA EZH2 NKC cells, CRISPR/Cas9 control vs 
CRISPR/Cas9 EZH2 NKC cells as well as upon treatment with the EZH2 
inhibitor Tazemetostat (EPZ6438). These analyses revealed that the 
expression of all eleven genes increases significantly upon genetic or 
pharmacological inhibition of the histone methyltransferase, although to 
different magnitudes in the different conditions (Figure 24). The western blot 
confirming successful reduction of H3K27me3 levels upon Tazemetostat 





Figure 24: Expression of direct EZH2 target genes increases upon EZH2 
depletion. 
qPCR validating the expression of the selected 11 EZH2 target genes in (A) shRNA 
control vs shRNA EZH2 NKC cells (B) CRISPR/Cas9 control vs CRISPR/Cas9 EZH2 
NKC cells (C) DMSO treated vs 500nM Tazemetostat (EPZ6438) (for 72 hours) 




Furthermore, we designed specific primers covering the TSS/promoter of the 
the selected target genes where a peak for EZH2 was detected. Also, for the 
negative control, we designed primers across the intragenic region of the gene 
where EZH2 occupancy was not observed. The individual ChIP qPCR analysis 
validated EZH2 occupancy as well as EZH2-dependent H3K27me3 and 






Figure 25: EZH2 binds to TSS of its target genes and mediates promoter specific 
histone modifications. 
qRT-PCR following EZH2- and histone modification ChIP analysis utilizing primers 
embracing the TSS/promoter region and intragenic region (negative control) of 
selected genes for validation as a direct EZH2 target gene.  
 
 
 EZH2-GATA6 axis in PDAC 
 EZH2 targets epithelial transcription factor Gata6  
One of the well-regulated and interesting EZH2 target genes was the 
transcription factor GATA6. GATA6 represents a critical regulator of pancreatic 
development and endodermal lineage differentiation (C. Y. Chia et al. 2019; 
Lorberbaum and Sussel 2017; Tiyaboonchai et al. 2017). Its expression in 
various cancers including pancreatic cancer is linked to blocking pancreatic 
carcinogenesis and PDAC progression. GATA6 loss is associated with reduced 
differentiation and increased metastasis in PDAC (Martinelli et al. 2017). 
Further evidence states that GATA6 activates transcriptional programs related 
to epithelial differentiation (Hermann et al. 2014; Martinelli et al. 2016). 
Moreover, all the PDAC subtype studies from this decade portray GATA6 as 
the central regulator of molecular subtype identity. GATA6 proves to be a 
surrogate marker with high and low GATA6 expression implying classical and 
basal-like PDAC subtypes, respectively (Aung et al. 2019; P. Bailey et al. 2016; 
Collisson et al. 2011; O’Kane et al. 2020).  
Interestingly, in our ChIP-seq we detected a prominent EZH2 peak around the 
TSS/promoter of the Gata6 gene. Additionally, we observed a decrease in 
H3K27me3 enrichment and increase in H3K4me3 occupancy in this region 
upon the depletion of EZH2. This was in line with our observations in RNA-seq 
data, where we detected a significantly enhanced upregulation of Gata6 
expression upon EZH2 knockdown (Figure 26A). To further validate that EZH2 
indeed binds specifically to the promoter of Gata6, we performed individual 
ChIP experiments. Consistent with our observations in IGV from ChIP-seq, 
qRT-PCR performed in ChIP samples revealed a significant enrichment of 
EZH2 binding and its activity (H3K27me3) around the promoter of Gata6. In the 




H3K4me3 and H3K27ac (active transcription marks) increased (Figure 26B). 
Moreover, the intragenic regions showed no difference in the enrichment of 
these marks (Figure 26B) verifying that all the binding and modifications occur 





Figure 26: EZH2 binds to TSS of Gata6 and mediates TSS specific histone 
modifications. 
(A) Integrative Genomics Viewer (IGV) profile from ChIP- and RNA-seq at the Gata6 
gene locus in NKC cells showing EZH2 binding and enrichment of H3K27me3 and 
H3K4me3 at the Gata6 gene in indicated conditions. Arrows indicate location of 
primers designed for individual ChIP validation studies shown in B. (B) qRT-PCR 
following EZH2- and histone modification ChIP analysis utilizing primers embracing the 
TSS/promoter region and intragenic region (negative control) of Gata6 for validation as 







 EZH2 depletion significantly increases Gata6 expression in murine 
PDAC cells   
We further aimed to scrutinize if EZH2 dependent Gata6 regulation could be 
validated in vitro in PDAC cell lines. Therefore, we investigated the EZH2-
Gata6 axis in various cell lines utilizing different genetic as well as 
pharmacological approaches to manipulate EZH2 expression and activity. 
Gata6 expression was upregulated both at the RNA and protein level upon 
shRNA- and CRISPR/Cas9-mediated EZH2 depletion (Fgure 27 A-D). 
Importantly, re-expression of EZH2 in EZH2 deficient NKC cells rescued Gata6 
upregulation (Figure 27 C&D). Moreover, Gata6 transcription was induced 
when NKC cells were treated with Tazemetostat (EPZ6438) (Figure 27 E), 
which specifically inhibits the histone methyltransferase activity of EZH2 
(Italiano et al. 2018; McGrath and Trojer 2015). The western blot shows the 
reduction in H3K27me3 levels upon treating NKC cells with Tazemetostat 
(EPZ6438), confirming that the inhibitor indeed reduced the enzymatic activity 
of EZH2 (Figure 27 F). This suggests that blockade of EZH2 activity is sufficient 
to re-install Gata6 expression. Furthermore, we analyzed Gata6 expression in 
primary PDAC cells derived from caNFATc1;KrasG12D (NKC) and 
EZH2fll+;caNFATc1;KrasG12D (ENKC) mice. As expected, there was an 
upregulation of Gata6 mRNA and protein levels in ENKC cells compared to 
NKC cells (Figure 27 G&H), further confirming Gata6 as a transcriptional EZH2 
target. To understand if the EZH2-Gata6 axis is restricted to PDAC models with 
constitutive NFATc1 expression or also functions similarly in other PDAC 
models, we used KPC PDAC cells. KPC cells are derived from the 
KrasG12D;TP53R172H/+ (KPC) mice. We subjected KPC cells to CRISPR/Cas9-
mediated knockout of Ezh2 and analyzed Gata6 expression in these cells. 
There was an upregulation of Gata6 mRNA and protein expression upon EZH2 
deletion (Figure 27 I&J), thereby confirming that EZH2-dependent repression of 






Figure 27: EZH2 deficiency leads to increased GATA6 expression in murine 
PDAC cells 
(A) qPCR and (B) western blot analyses depicting increased GATA6 expression in 
NKC cells upon shRNA-mediated EZH2 knockdown. (C) qPCR showing decrease in 
Gata6 expression upon re-expression of EZH2 in CRISPR/Cas9-mediated EZH2 
knockout NKC cells. (D) Western blot analyses depicting increased GATA6 expression 
in NKC cells upon CRISPR/Cas9 mediated EZH2 knockout cells. (E) qPCR illustrating 
reduction in Gata6 expression upon treatment of NKC cells with EZH2 inhibitor 
Tazemetostat (EPZ6438). (F) Expression analysis of H3K27me3 levels to confirm 
successful treatment with Tazemetostat (EPZ6438) (500 nM for 72 hours). H3 is the 
loading control. (G) qPCR and (H) western Blot analyses depicting increased GATA6 
expression in primary PDAC cells derived from  EZH2fll+;caNFATc1;KrasG12D (ENKC) in 
comparison to PDAC cells derived from  caNFATc1;KrasG12D (NKC) mice. (I) qPCR 
and (J) Western Blot analyses depicting increased GATA6 expression in KPC cells 
upon CRISPR/Cas9 mediated EZH2 knockout. Two-way ANOVA was used to check 




 EZH2 represses GATA6 expression in human PDAC 
Our next question was to understand whether EZH2-dependent GATA6 
repression also occurs in human PDAC. First, we took advantage of publicly 
available EZH2 ChIP-seq data accomplished in PANC-1 (Tzatsos et al. 2013). 
PANC-1 is a human pancreatic cancer epithelial cell line which is categorized 
as a basal-like subtype PDAC cell line (Diaferia et al. 2016). The ChIP-seq raw 
data was retrieved and analyzed in usegalaxy server using the default 
parameters. The EZH2 enrichment profile was visualized on IGV which 
revealed a significant enrichment of EZH2 on the GATA6 TSS/promoter (Figure 
28A), confirming that EZH2 binds on the GATA6 gene in human PDAC as well. 
To validate whether EZH2 also blocks GATA6 transcription, we subjected 
PANC-1 cells to CRISPR/Cas9 mediated EZH2 deletion and tested for GATA6 
expression in CRISPR/Cas9 control vs CRISPR/Cas9 EZH2 KO PANC-1 cells. 
As predicted, EZH2 deletion significantly increased GATA6 mRNA and protein 
expression (Figure 28B&C), yet again supporting that the EZH2-GATA6 axis 
also persists in human PDAC. 
 
 
Figure 28: EZH2 regulates GATA6 expression in human PDAC cell line PANC-1. 
(A) IGV profile demonstrating EZH2 occupancy on the GATA6 TSS in PANC1 cells as 
defined by ChIP-seq analysis (Tzatsos et al. 2013). (B) qPCR and (C) western blot 
analyses depicting increased GATA6 expression in PANC-1 cells upon CRISPR/Cas9-
mediated EZH2 knockout. Two-way ANOVA was used to check the significance of the 




We further aimed to validate the EZH2-GATA6-axis in Patient-derived xenograft 
(PDX) models. PDX models are currently largely used as preclinical model 
systems (Li 2015; C. Xu et al. 2019). We took advantage of PDAC PDX models 
established in our department which have been utilized to generate primary 
PDX derived PDAC cells. We utilized cells (GCDX5) generated from one of the 
PDX tumors (PDX5) to explore EZH2-mediated Gata6 repression. When we 
exposed these cells to siRNA-mediated EZH2 knockdown, we observed a 
significant upregulation of GATA6 mRNA and protein. Moreover, the 
pharmacological blockade of EZH2 activity by treating GCDX5 cells with EZH2 
inhibitor also increased GATA6 transcription. These results further strengthen 




Figure 29: EZH2 regulates GAT6A expression in cells derived from PDX models. 
(A) qPCR and (B) western blot analyses depicting increased GATA6 expression in 
GCDX5 cells upon siRNA-mediated knockdown of EZH2. (C) qPCR and (D) western 
Blot analyses depicting increased GATA6 expression in GCDX5 cells upon and 
Tazemetostat (EPZ6438) treatment (1 µM for 72 hours). Two-way ANOVA was used to 




 The EZH2-GATA6 axis exists in human PDAC specimens 
To further investigate the significance of the EZH2-GATA6 axis in human 
PDAC patient specimens, we performed immunohistochemical staining 
analyses of GATA6 in the PDAC TMA mentioned in Figure 5. We applied the 
immunoreactive score (IRS) to quantify GATA6 expression in each sample. 
Tissues with IRS ≤ 3 were considered as tissues with low GATA6 levels and 
tissues with IRS > 3 were considered as high GATA6 expressing tissues. IRS 
of GATA6 was further correlated with the IRS of EZH2. Remarkably, GATA6 
expression was reduced in a significant number of EZH2-high tumors (Figure 
30), indicating that EZH2-dependent GATA6 repression is evident in a 
subgroup of human PDAC specimens. Taken together, these data suggest that 
EZH2-GATA6 axis also exists in human PDAC. 
 
Figure 30: EZH2 dependent GATA6 regulation is evident in the subpopulation of 
PDAC patients. 
(A) Representative images from two PDAC patients showing EZH2 and GATA6 
expression in human PDAC tissue. Magnification -100X and 400X; Scale bar – 100 µm 
and 10 µm. (B) Graph depicting GATA6 expression in patients expressing low (IRS ≤ 
3) and high (IRS > 3) EZH2 expression. Each dot represents a patient from the TMA 
described in Figure 5. Values represent mean ± SD. Significance was determined by 




 GATA6 targets are enriched upon EZH2 depletion  
To explore whether EZH2 also interferes with transcription programs regulated 
by GATA6, we utilized publicly available GATA6 ChIP- and RNA- seq data in 
PDAC (Martinelli et al. 2016). From the GATA6 ChIP-seq data, we set a 
threshold of FDR < 1 to the output from Diffbind and analyzed those GATA6 
binding regions using the GREAT tool to obtain the genes associated with 
these regions. We thereby identified 7065 GATA6 target genes. Subsequently, 
we intersected those direct GATA6 target genes with genes for which RNA-seq 
analysis revealed a significant (q ≤ 0.05) downregulation upon knockout of 
Gata6 (172 genes). Hence, we discovered 58 significant genes that are bound- 
and activated by GATA6 (Figure 31A). Subsequently, we performed GSEA with 
these GATA6 targets on our transcriptome data. Interestingly, GATA6 targets 
were positively enriched upon EZH2 depletion (Figure 31B), suggesting that 





Figure 31: Direct downstream targets of GATA6 are enriched upon EZH2 
depletion.  
(A) Venn diagram showing direct Gata6 target genes which are transcriptionally 
activated by the transcription factor as identified by Martinelli et al (Martinelli et al. 
2016). (B) GSEA plot showing enrichment of Gata6 targets identified in A upon EZH2 







 Gata6 knockdown can rescue the effects of EZH2 depletion on 
invasion 
In order to explore the functional significance of GATA6 in curbing EZH2 
mediated PDAC progression, we depleted Gata6 in shRNA EZH2 NKC cells 
using siRNA strategies. Figure 32A depicts the confirmation of knockdown of 
Gata6. Subsequently, we performed an invasion assay to investigate whether 
Gata6 knockdown can rescue the invasive capacity of EZH2-deficient PDAC 
cells. The number of invading cells increased significantly upon Gata6 
knockdown in EZH2-depleted cells (Figure 32B), arguing that Gata6 depletion 
partially restores the invasive potential of shRNA EZH2 NKC cells. These 
results suggest that Gata6 repression is essential for EZH2-driven PDAC cells 
invasion. 
To further understand the role of GATA6 in impeding the EZH2-dependent 
repression of gene signatures associated with the classical PDAC subtype, we 
examined the expression of few classical genes in the presence and absence 
of EZH2 and upon GATA6 depletion. The classical genes were selected from 
the previously described Pure-classical gene set defined by Puleo and 
colleagues (Puleo et al. 2018). Consistent with the observed enrichment of pure 
classical and basal-like gene signatures in shRNA EZH2 and shRNA control 
NKC cells, respectively, pure classical genes were upregulated upon sole 
EZH2 depletion. However, GATA6 depletion partially rescued increased 
classical target gene expression observed upon EZH2 deficiency (Figure 32C) 
suggesting that GATA6 is required for EZH2 mediated abrogation of classical 
gene expression signatures. 
Taken together, these data demonstrate that GATA6 expression is essential for 
the abrogation of invasive potential of features of PDAC and acquisition of a 









Figure 32: GATA6 knockdown partially rescues the invasion effects mediated by 
EZH2 deficiency. 
(A) qPCR demonstrating successful knockdown of Gata6 in shRNA EZH2 NKC cells. 
(B) Boyden chamber assay to determine NKC cell invasion in the presence and 
absence of EZH2 and upon Gata6 depletion. (C) qPCR performed in NKC cells to 
evaluate a selection of target genes associated with the pure classical PDAC subtypes 
as defined by Puleo et al (Puleo et al. 2018). Two-tailed unpaired student’s t-test was 
used to test the statistical significance. 
 
In summary, our findings link transcriptional GATA6 repression to EZH2-
dependent tumor progression in PDAC and suggest that pharmacological 
interference with EZH2 activity in a subset of PDAC patients can re-install 










 Polycomb group proteins in the regulation of differentiation 
processes 
Polycomb group (PcG) proteins regulate several processes during development 
including cell fate determination, lineage specification, stem cell regulation and 
maintaining homeostasis (Bracken et al. 2006; Ringrose and Paro 2004; 
Schuettengruber and Cavalli 2009; Surface, Thornton, and Boyer 2010). In the 
course of embryonic development, they control transcriptional programs by 
restricting the expression of specific genes. They particularly repress genes 
linked to differentiation and maintain the repressed state of the genes in an 
adult differentiated cell (Sparmann and Van Lohuizen 2006). Along with their 
critical role in development and differentiation, several studies show a 
significant connection between polycomb proteins and cancer (Hormaeche and 
Licht 2007; Richly, Aloia, and Di Croce 2011; Sauvageau and Sauvageau 
2010; Valk-Lingbeek, Bruggeman, and Van Lohuizen 2004). PcG proteins carry 
out their functions by forming multiprotein complexes like PRC1 and PRC2. 
EZH2 is one of the most important members of the PRC2 complex and is found 
to be vital in ensuring proper development of various organs including the 
pancreas (Chou et al. 2015; San et al. 2016). This is very well reflected in our 
study where we see that pancreas specific homozygous EZH2 knockout mice 
are lethal and show various developmental abnormalities of the pancreas. 
 EZH2 in pancreas development and cancer progression 
Since the past few years, EZH2 has gained a lot of attention regarding its 
deregulation in various cancer entities. For instance, EZH2 overexpression is 
seen in breast and prostate cancer, linking its abundant expression to poor 
prognosis and advanced tumor stages (Bachmann et al. 2006; Kleer et al. 
2003). Similarly, in pancreatic cancer, consistent with previous studies (N. M. 
Chen et al. 2017; Ougolkov, Bilim, and Billadeau 2008), our findings also show 
increased EZH2 levels in dedifferentiated high-grade human PDAC.  
EZH2 overexpression in cancer has been associated with increased 
proliferation (Ougolkov, Bilim, and Billadeau 2008), stemness (Y. H. Chen, 





and metastasis (Rao et al. 2010; Richter et al. 2009). In line with these reports, 
we made similar observations upon performing functional assays in NKC PDAC 
cells in vitro. Upon EZH2 depletion, cells exhibited reduced proliferation, 
anchorage-independent growth and invasive capabilities confirming that EZH2-
deficient cells reduce their tumor-promoting activities. One of the reasons for 
the failure to sufficiently eradicate cancer cells has been credited to the 
stemness property of cancer cells which lead to therapy resistance and tumor 
relapse (Nangia-Makker, Hogan, and Raz 2018; Shlush et al. 2017). Our 
sphere-formation assay in NKC PDAC cells depicts that upon loss of EZH2, 
NKC cells lose their stemness property. Accordingly, the RNA-seq analysis 
suggests that EZH2 regulates transcriptional programs that mediate stemness 
in PDAC cells. These findings argue that EZH2 depletion can create a shift 
towards reduced stemness features which might reduce the likelihood of PDAC 
relapses.  
We utilized the caNfatc1;KrasG12D transgenic mouse models with wildtype Ezh2 
expression or upon heterozygous Ezh2 expression to investigate the 
implications of EZH2 depletion in PDAC in vivo. Although homozygous mice 
would aid better in characterizing the role of EZH2, the heterozygous mice 
already displayed differences regarding changes in cellular differentiation status 
and metastasis. Despite the EZH2-status dependent differences in tumor 
biology in these models, we did not observe significant differences between the 
survival of caNfatc1;KrasG12D and EZH2fl/+;caNfatc1;KrasG12D mice. Given that 
EZH2 is critical for proper development of the pancreas and based on our 
observation that EZH2 heterozygous mice of advanced age displayed initial 
signs of pancreatic insufficiency and atrophy, the comparable median survival 
between the groups can be best explained by developmental issues. We 
speculate that the utilization of an inducible mouse model (Guerra and Barbacid 
2013; Martinelli et al. 2016) which facilitates EZH2 depletion after the 
completion of pancreatic development would favor a better judgment on the 
impact of EZH2 activity on tumor progression and mice survival. However, our 
GEMM harboring EZH2 heterozygous deficiency already displays reduced 
tumor incidence and metastasis. Hence, despite the limitations of our PDAC 




caNfatc1;KrasG12D mouse model harbor the oncogenic KrasG12D mutation and 
constitutive expression of the inflammatory transcription factor NFATc1. 
Considering the implication of inflammation in boosting PDAC development 
(Baer et al. 2014; Yadav and Lowenfels 2013; Ye et al. 2019; Young et al. 
2019), this well-characterized transgenic mouse serves as a good model 
system to study PDAC carcinogenesis. Additionally, these mice undergo all 
steps of pancreatic carcinogenesis, thus highly mimicking human PDAC 
development (Baumgart et al. 2014). Besides, Cre-mediated expression of HA-
tagged NFATc1 in this model occurs constitutively under the control of the 
Rosa26 promoter, thus prohibiting the previously described alterations (N. M. 
Chen et al. 2017) of NFATc1 expression upon interference with EZH2 activity. 
Furthermore, EZH2 has been identified as a transcriptional NFATc1 target gene 
(Baumgart et al. 2014) which means NKC mouse model expresses high levels 
of EZH2, thus characterizing this model as a practicable tool to study the tumor 
biological consequences and the mechanistic basis of EZH2 overexpression in 
PDAC. However, in the context of constitutive NFATc1 activation, homozygous 
Ezh2 depleted mice are lethal which hinders us from examining homozygous 
EZH2 loss in these mice. Interestingly, in another GEMM which is also based 
on KrasG12D but shows endogenous NFATc1 expression (EZH2fl/fl;KrasG12D 
(KEC)), this was not to be observed and the mice were viable even upon 
homozygous Ezh2 depletion (N. M. Chen et al. 2017; Mallen-St. Clair et al. 
2012). Hence, constitutive NFATc1 activation seems to potentiate the functional 
implications of Ezh2 deficiency in PDAC development. However, the EZH2-
GATA6 axis was also confirmed in systems with endogenous NFATc1 
expression and in the context of additional genetic drivers of PDAC (e.g. gain of 
function mutations of TP53). 
Although the functional implications of EZH2 in cancer are published in various 
reports (Y. H. Chen, Hung, and Li 2012; Han et al. 2016; Ougolkov, Bilim, and 
Billadeau 2008; Rao et al. 2010; Richter et al. 2009; Smits et al. 2010), very few 
studies exist that decode the specific function of this histone methyltransferase 
in PDAC. Consistently, very little is known about the mechanistic functions and 
direct targets of EZH2, especially in pancreatic cancer. Our study describes 
ChIP- and RNA-seq analysis which provides insights into the mechanistic 





activity to suppression of transcriptional programs fostering differentiation and a 
better outcome of PDAC patients.  
 Role of epigenetic modulations in mediating cancer cell plasticity 
Cancer cells have a high level of cellular and molecular plasticity which is 
predominantly regulated at the level of gene transcription (Flavahan, Gaskell, 
and Bernstein 2017). Their ability to interconvert between different states allows 
them to grow and spread across different sites (Roe et al. 2017). EMT and 
stemness represent crucial factors for cancer cell plasticity which have a major 
impact on metastasis and therapeutic resistance, respectively (Polyak and 
Weinberg 2009). Many epigenetic modulators regulate transcription programs 
that drive this transition. For instance, epigenetic alterations initiated by 
transcription factors like SNAI and ZEB1 modulate the chromatin, consequently 
controlling the transcription of genes involved in EMT (Nieto et al. 2016). In a 
study in small cell lung cancer (SCLC), amplification of the transcription factor 
NFIB offered genome-wide chromatin accessibility subsequently promoting 
gene expression controlling metastasis programs (Denny et al. 2016). Recent 
evidence suggests that reprogramming of the enhancer landscape mediates 
metastatic potential in pancreatic cancer cells (Roe et al. 2017). Few studies 
indicate the role of EZH2 in interacting with EMT associated factors. For 
instance, EZH2 promotes Snail-mediated recruitment of RING1A/B to the 
CDH1 promoter (encoding for E-Cadherin) to repress its expression, thereby 
promoting cell migration in PANC-1 cells (Chen et al. 2014). Furthermore, few 
studies also suggest that EZH2 binds directly to the CDH1 promoter to repress 
its expression, thus promoting cell migration and invasion (Han et al. 2016; 
Qazi et al. 2012). However, in our study, we do not observe any major 
differences in the expression of EMT-related gene signatures upon loss of 
EZH2. Interestingly we still discovered a potential link between EZH2 
expression and metastasis in vivo. However, there are a few reports suggesting 
EMT-independent mechanisms driving PDAC metastasis in GEMMs. For 
instance, Zheng et al demonstrate that loss of Twist1 and Snai1 does not 
influence metastases frequency (Zheng et al. 2015) and further fluorescence-
based lineage tracing experiments confirmed non-EMT associated metastasis 




arguing that the EMT process is dispensable for metastasis in PDAC, we 
contemplate a possibility that metastasis could have been influenced by 
processes other than EMT in our mouse models. It is also possible that the 
implication of EZH2 on EMT was prominent in mice but not as well captured in 
our in vitro systems. To better understand the implication of EZH2 on EMT in 
vivo, the tumors from the wildtype and EZH2 depleted mice could be stained 
with antibodies recognizing EMT markers. 
There are few studies in breast cancer investigating the differences in 
epigenomic patterns between primary and metastatic sites. Priedigkeit and 
colleagues showed in their study that 20 % of patients with ERBB2-HER2 
negative tumors at the primary tumor site showed ERBB2/HER2 positive brain 
metastasis (Priedigkeit et al. 2017). In a recent report by Cai et al., they studied 
the transcriptional differences between cells from tumors in primary and 
metastasized sites (brain and lung) of breast cancer utilizing high throughput 
sequencing approaches (ChIP-seq, RNA-seq, ATAC-seq, and HiChIP). They 
claim that very few of those differences are driven by genetic mutations, while 
the majority of these are promoted by epigenetic alterations indicating the 
relevance of epigenomic reprogramming in fostering cellular plasticity of cancer 
(Cai et al. 2020). Similarly, pancreatic cancer, which is a highly heterogeneous 
tumor, also displays a high degree of cellular plasticity which is largely 
mediated by differences in epigenetic landscapes. Lomberk et al. performed a 
comprehensive analysis of epigenomic landscapes underlying PDAC subtypes 
in patient-derived tumor xenografts (PDTXs) combining ChIP-seq for various 
histone marks, RNA-seq and DNA methylation approaches where they 
associate the epigenomic pattern with PDAC heterogeneity. Moreover, they 
identify MET as a crucial transcription factor expressed in basal-like PDAC 
subtypes and also show that siRNA mediated depletion of MET in PDTX-
derived cell lines mediates a shift from basal to classical PDAC subtype, 
highlighting the influence of epigenetics in PDAC plasticity (G. Lomberk et al. 
2018). Considering the implications of EZH2 in promoting metastasis and 
stemness in our studies, manipulating EZH2 expression to tackle PDAC 





 EZH2 in PDAC subtype identity 
In the last decade, various molecular subtypes of PDAC have been described. 
Although just a few genes overlap between different classification systems and 
despite discrepancies in the definition of molecular PDAC subtypes, two 
subtype classes were consistently represented throughout these studies and 
were found to have prognostic relevance – basal-like (also called squamous or 
quasi-mesenchymal (QM)) and classical subtypes (P. Bailey et al. 2016; 
Collisson et al. 2011; Moffitt et al. 2015; Puleo et al. 2018). While the basal 
subtype is correlated with a higher tumor grade and poor survival, the classical 
subtype is relatively well-differentiated and exhibits a better prognosis (P. 
Bailey et al. 2016; Collisson et al. 2011).  
 
Figure 33: Schematic depicting two main PDAC subtypes and its features. 
Two PDAC subtypes represented in all subtyping studies combined are basal-like and 
classical PDACs. There is a clear distinction between the features of these two 
subtypes regarding differentiation status, survival, prognosis, metabolism, gene 





Molecularly, basal tumors show increased TP63 expression (Mueller et al. 
2018) and express genes related to EMT (Martens et al. 2019; Nicolle et al. 
2017). In contrast, classical tumors are characterized by expression of 
pancreatic developmental transcription factors and epithelial genes (P. Bailey et 
al. 2016). Dissimilar with classical subtypes, basal subtypes lose expression of 
master endodermal transcription factors that are required to maintain 
endodermal differentiation (Adamo et al. 2017). Additionally, basal subtypes 
regularly carry mutations in genes encoding chromatin regulatory proteins like 
KDM6A (Andricovich et al. 2018). Reports also suggest a correlation of PDAC 
subtypes with metabolism. While basal tumors are enriched for genes 
regulating glycolytic pathways, classical tumors show enrichment for lipogenic 
pathways (Daemen et al. 2015; Martens et al. 2019; Nicolle et al. 2017). 
Evidence also suggests that these subtypes differ in their responses to 
chemotherapy where basal tumors show an overall worse chemotherapeutic 
response compared to classical tumors (Aung et al. 2019; P. Bailey et al. 2016; 
Collisson et al. 2011; O’Kane et al. 2020). Together, there exists evidence for a 
classical/basal-like subtype system in PDAC which embodies prognostic and 
predictive relevance. Hence, molecular-subtype-driven stratification in PDAC 
treatment might represent a promising strategy to tackle PDAC.  
Differential gene expression analysis performed in our study revealed that 
EZH2 loss led to the enrichment of transcriptional programs fostering a 
favorable prognosis and promoting differentiation as well as a classical PDAC 
subtype state. Additionally, basal-like gene signatures were negatively enriched 
upon EZH2 depletion. These observations point out to a possibility of the 
existence of the EZH2-high subgroup in the basal-like PDAC subtype. 
However, we did not observe differences in EZH2 expression per se between 
classical and basal-like PDAC subtype states in the published datasets (P. 
Bailey et al. 2016; Diaferia et al. 2016; Puleo et al. 2018). This confirms that the 
expression of EZH2 alone cannot be used as a predictive marker to determine 
the subtype. To understand if manipulating EZH2 truly converts PDAC tumors 
from basal to classical PDA tumors, EZH2 could be depleted in basal tumors 
and further the EZH2 proficient and deficient basal tumors can be analyzed for 
classical/basal PDAC features by staining for classical markers (E-Cadherin, 





speculate that EZH2 functions by repressing the classical genes rather than 
modulating the basal genes.  
 GATA6 as a marker of the classical PDAC subtype 
The transcription factor that was consistently mentioned in all PDAC molecular 
subtyping studies was GATA6. The classical PDAC subtype defined by both 
Moffit and Collison expressed elevated levels of GATA6 (Collisson et al. 2011; 
Moffitt et al. 2015). Furthermore, Bailey et al. reported that GATA6 was 
epigenetically repressed in the squamous subtype (P. Bailey et al. 2016). The 
aforementioned subtyping studies and various other reports (G. Lomberk et al. 
2018; Puleo et al. 2018; Seino et al. 2018; The Cancer Genome Atlas 
Research Network and Raphael 2017) characterize the expression and activity 
of GATA6 as the crucial driver of PDAC subtype identity. 
GATA6 belongs to the family of GATA transcription factors that contains two 
highly conserved zinc-finger DNA-binding domains that recognize an 
(A/T)GATA(A/G) consensus nucleotide sequence. There are six GATA 
members: while GATA 1-3 are predominantly expressed in the hematopoietic 
lineage, GATA 4-6 are mainly present in the endodermal lineage (Rodríguez-
García, Sola-Landa, and Barreiro 2017; Tiyaboonchai et al. 2017). GATA6 
drives endodermal lineage differentiation by transcriptionally activating lineage 
defining transcription factors (Fisher et al. 2017). Consistently, Gata6 maintains 
epithelial differentiation and suppresses mutant Kras-driven tumorigenesis in 
the mouse pancreas by activating differentiation-related transcription programs 
(Martinelli et al. 2016).  
In pancreatic cancer models, GATA6 blocks dedifferentiation and abrogates 
EMT programs. Moreover, dedifferentiated basal-like PDAC tumors with low 
GATA6 expression associate with poor prognosis and low response to 5-
fluorouracil (5-FU) based adjuvant therapy (Martinelli et al. 2017). In addition to 
these studies, results from the COMPASS trial identified GATA6 expression as 
a robust surrogate biomarker for differentiating classical and basal PDAC 
subtypes utilizing RNA sequencing and RNA in situ hybridization (ISH) 
techniques (Aung et al. 2019). Besides, in the same COMPASS trial samples, 




subtype, while its expression is low or almost absent in basal-like tumors 
(O’Kane et al. 2020).  
Utilizing high throughput sequencing approaches, our findings identified Gata6 
as a key target of EZH2-dependent transcriptional repression in PDAC. 
Notably, GATA6 depletion in EZH2 deficient cells re-installed the invasive 
potential of PDAC cells and also decreased the expression of classical PDAC 
subtype genes, implying that EZH2-mediated GATA6 repression is crucial for 
the tumor-promoting activities of the histone methyltransferase. However, to 
what extend GATA6 expression impacts on EZH2-driven PDAC biology 
remains to be elucidated, for instance by utilizing in vivo models with and 
without Gata6 expression in the absence of EZH2. 
 PDAC subtype switching 
PDAC subtypes are controlled at the level of transcription (P. Bailey et al. 2016; 
Collisson et al. 2011; Moffitt et al. 2015; Puleo et al. 2018). Considering that 
PDAC exhibits a high degree of plasticity and given that epigenetic alterations 
are reversible, PDAC subtypes are potentially interconvertible. Importantly, 
classical PDAC tumors exhibit a better prognosis and higher chemotherapeutic 
susceptibility, thus underinning that subtype switching towards the classical 
PDAC subtype constitutes an attractive strategy in PDAC treatment. Subtype 
switching has for instance been reported for basal-like PDAC subtypes 
harboring mutations in the histone demethylase encoding gene KDM6A. Loss 
of KDM6A fosters aberrant rewiring of super-enhancers regulating oncogenes 
such as ΔNp63, RUNX, and MYC, thereby promoting dedifferentiation to the 
squamous-like subtype and metastatic PDAC. Furthermore, the study confirms 
in vivo that KDM6A-deficient PDAC is more susceptible to BET inhibitors which 
reverse basal differentiation and restrain PDAC growth. Overall, this study 
reveals reprogramming of super-enhancers as a crucial mechanism for subtype 
switching in pancreatic cancer (Andricovich et al. 2018). Besides the chromatin 
regulatory proteins that control subtype-defining transcription programs, 
subtype switching is also controlled by pioneer transcription factors. For 
instance, Adams and colleagues provide detailed evidence stating Glioma-
associated oncogene homology 2 (GLI2) transcription factor as the critical 





was found to be highly expressed in basal-like pancreatic cancer cell lines and 
patient tissues. GLI2 activation could sufficiently switch PDAC cells from 
classical to basal-like subtype harboring enhanced EMT potential. Additionally, 
depletion of this transcription factor could suppress basal transcription 
programs, suggesting interfering with GLI2 activity might provide a promising 
strategy to push PDAC cells towards a less aggressive, classical subtype 
(Adams et al. 2019). These studies emphasize the significant degree of 
plasticity modulated by the chromatin factors and transcription factors in PDAC 
subtypes.  
 Strategies to induce GATA6 expression for subtype switching 
Switching from one subtype to another involves transcriptional reprogramming 
of endodermal developmental and differentiation programs. Considering the 
involvement of GATA6 in PDAC development, progression and differentiation 
(Hermann et al. 2014; Martinelli et al. 2016, 2017) and its implications in the 
classical PDAC subtype (Adams et al. 2019; Aung et al. 2019; P. Bailey et al. 
2016; Collisson et al. 2011; Moffitt et al. 2015; O’Kane et al. 2020; Puleo et al. 
2018), upregulation of GATA6 expression is an attractive strategy to promote 
and maintain classical subtype identity. Consistently, the induction of GATA6 
was observed in tumors upon switching from basal to classical subtypes in lung 
and skin cancers (Biehs et al. 2018). Furthermore, the downregulation of 
GATA6 mediated commitment to squamous subtype in lung cancer models 
(Cheung et al. 2013). Consistently, similar observations are made in PDAC 
subtype inter-conversion. For instance, while GATA6 expression declined in 
GLI2-induced basal PDAC cells, loss of GLI2 resulted in increased GATA6 
expression and acquisition of classical gene signatures (Adams et al. 2019). 
Similarly, genetic depletion of the hepatocyte growth factor receptor MET in 
basal PDAC subtypes resulted in a shift towards the classical phenotype which 
involved upregulation of GATA6-dependent transcription programs (G. Lomberk 
et al. 2018). These studies emphasize the role of the transcriptional regulator 
GATA6 in subtype switching in pancreatic cancer. However, the strategies to 
re-induce GATA6 expression are not well understood. 
First insights on the dynamic regulation of GATA6 expression came from 




regulation of GATA6 expression occurs at the chromatin level (Fisher et al. 
2017; Smith, Singh, and Dalton 2010; Suzuki et al. 2015), for instance by 
transcriptional repression by PcG proteins. Gata6 expression is found to be 
tightly regulated by polycomb proteins during cardiac development (Kang et al. 
2010). Furthermore, genome-wide shRNA screening in embryonic stem cells 
identified BCOR, an associated member of the PRC1 complex member 
RING1B as an essential repressor of the GATA6 gene (Cooper and Brockdorff 
2013). Further emphasizing the impact of the PcG family of chromatin 
regulatory proteins in GATA6 regulation, the PRC2 core member EED 
maintains neural stem cell differentiation by repressing GATA6 transcription 
(Sun et al. 2018). Finally, loss of the histone methyltransferase EZH2 in mouse 
embryos resulted in the differentiation of germ layers due to the de-repression 
of Hoxb1, Hand1, and Gata6 (Huang et al, 2014).  
However, the mechanisms controlling the expression of GATA6 in cancer 
remain mainly elusive. Our study explored EZH2 dependent Gata6 regulation in 
vitro in different PDAC murine (NKC, KPC) and human (PANC-1) cell lines 
upon transient knockdown and stable knockout of EZH2 as well as upon 
pharmacological EZH2 inhibition. Additionally, EZH2-dependent GATA6 
regulation was recognized in PDX specimens at both mRNA and protein levels. 
Our analysis in human samples also revealed a subgroup of PDAC patients 
with EZH2 high/GATA6 low tumors, and these patients might be potentially 
exhibiting EZH2 dependent GATA6 regulation. Combining all the data, our 
findings identify a novel mechanism of GATA6 regulation in PDAC. EZH2 
regulates Gata6 at the transcriptional level by binding on the TSS/promoter of 
the Gata6 gene and depositing the H3K27me3 repressive mark. Upon loss of 
EZH2, there is a reversal of this regulation which leads to increased Gata6 
transcription and enrichment of GATA6 downstream targets. However, the 
mechanism behind the recruitment of EZH2 to the Gata6 locus is yet to be 
discovered. We have observed before that NFATc1 regulates EZH2 expression 
in PDAC (Baumgart et al. 2014) and biochemically interacts with the 
methyltransferase (unpublished data of the Hessmann group). Hence, NFATc1 
might recruit EZH2 to the Gata6 promoter. Furthermore, one of the previous 
report suggest KDM2B-mediated EZH2 recruitment to the Gata6 locus (Tzatsos 





remains to be elucidated, our data suggest EZH2 inhibition as a promising 
strategy to re-install GATA6 expression in a subgroup of PDAC.  
 Pharmacological inhibition of EZH2 in PDAC 
EZH2 is a very attractive target in cancer therapy due to its oncogenic potential 
in various cancer types (Raman et al. 2005; Rao et al. 2010; Völkel et al. 2015; 
Zingg et al. 2015). Consequently, EZH2 inhibition was evaluated as a 
therapeutic strategy in many cancer entities (Huang et al. 2015a; McCabe et al. 
2012; Miele et al. 2017; Tan et al. 2007). Besides, the data on the safety and 
efficacy of EZH2 inhibitors is already available from clinical trials in 
hematological malignancies and selected solid tumors (e.g. NCT04179864, 
NCT03010982). Consequently, pharmacological interference with EZH2 activity 
represents a therapeutic option with strong translational potential in PDAC. 
However, as described before in chapter 1.4.2, epigenetic mechanisms in 
general, and EZH2 activity in particular, underlay a strong context-dependency. 
Consequently, we proposed that the efficacy of EZH2 inhibition as a therapeutic 
strategy in PDAC might be restricted to a subgroup of PDAC which 
encompasses those molecular prerequisites required for beneficial EZH2 
inhibition.  
Given that our data suggest transcriptional repression of GATA6 as an 
essential mechanism underlying oncogenic EZH2 activity, we propose that the 
therapeutic efficacy of EZH2 inhibition is restricted to a subgroup of PDAC 
patients characterized by high EZH2 activity and low GATA6 expression. In this 
particular context, the EZH2 blockade might sufficiently re-install GATA6 
expression with a subsequent shift towards gene signatures essential for 
maintaining classical subtype identity. Based on our analysis in human PDAC 
tissue the subgroup of EZH2high/GATA6low PDAC subtypes represents 
approximately 40 % of PDAC patients. While pharmacological interference with 
the EZH2-GATA6 axis might be beneficial in this subset of PDAC, EZH2 
inhibition might eventually prove less efficient in tumors which are either 
characterized by low EZH2 expression and activity and/or already express high 
levels of GATA6. Indeed, EZH2-independent mechanisms controlling GATA6 
expression have been reported previously. For instance, some cancer entities 




Y. Chia et al. 2015; Lin et al. 2012) which detangles the transcription factor 
from upstream transcriptional regulation. The chromosome location 18q11 is 
found to be prone to encounter copy number variations, particularly 
amplification, and the most important target gene of the copy number increase 
in this location indeed is GATA6 (Fu et al. 2008; Murphy et al. 2016). Integrated 
genetic and transcriptional analysis revealed GATA6 amplification in (4/42) 9.5 
% of PDAC samples (Fu et al. 2008) and in 19 % of xenograft specimens (Kwei 
et al. 2008). GATA6 amplification correlated with an increase in mRNA levels 
and further translated into increased protein expression (Fu et al. 2008). A 
recent study by Yue et al observed GATA6 copy number gains in 16 % of 
PDAC cases, but they also noted that there was a large population of classical 
PDAC tumors with high GATA6 expression without amplification of the gene 
(Chan-Seng-Yue et al. 2020). Mechanistically, upon GATA6 amplification, 
GATA6 positively activates Wnt signaling by negatively regulating the Wnt 
signalling pathway antagonist DKK1. Furthermore, PDAC patients harboring a 
GATA6 gain displayed high overall survival (Zhong et al. 2011). However, with 
regard to GATA6 amplification in PDAC, EZH2 inhibition of those PDAC 
subtypes might not result in a further increase in GATA6 expression, thus 
limiting its therapeutic potential. Further studies, for instance in vivo EZH2 
inhibition in GATA6low and GATA6high PDAC models are required to fully 
address this hypothesis.  
 
Figure 34: Proposed model depicting subtype switching in PDAC mediated by 
inhibiting EZH2. 
A population of basal-like PDAC exhibits high EZH2 and low GATA6 expression. Upon 





is abolished which in turn de-represses GATA6 transcription and mediates switching to 
a less aggressive classical PDAC subtype (Adapted and modified from Adams et al. 
2019).  
 
Taken together, EZH2 inhibition might prove as an advantage in the treatment 
of a subset of basal-like PDAC subtype patients exhibiting high EZH2 and low 
GATA6 expression. Therefore, it is important to apply molecular stratification 
approaches before advising EZH2 inhibition in PDAC therapy. 
 Conclusion 
The key findings of this study are: 
1. EZH2 has oncogenic potential in PDAC and mediates tumor 
progression, dedifferentiation, metastasis and PDAC plasticity. 
2. Loss of EZH2 results in the enrichment of gene signatures favoring 
better prognosis, differentiation and a classical PDAC subtype state. 
3. EZH2 transcriptionally represses GATA6, which is a crucial epithelial 
transcription factor. 
4. Genetic or pharmacological inhibition of EZH2 can re-install GATA6 in 
PDAC cells, which further abrogates tumor-promoting functions of EZH2. 
In summary, our findings link transcriptional GATA6 repression to EZH2-
dependent tumor progression in PDAC and suggest that pharmacological 
interference with EZH2 activity specifically in a defined subset of PDAC patients 
can re-install GATA6 expression in favor of a less aggressive and better 
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We established CRISPR/Cas9 mediated knockout of Ezh2 in NKC cells. The 
CRISPR/Cas9 control and CRISPR/Cas9 Ezh2 NKC cells were given for 
sequencing to confirm the knockout of Ezh2 at the genome level. Further, we 
isolated the lysate from these cells and validated the absence of EZH2 in the 
western blot. The cells were seeded in triplicates and harvested for RNA. 
Further, they were subjected to high throughput RNA sequencing. Before 
proceeding with the analysis, we carried out the quality check and Principal 
component analysis (PCA) through which we confirmed the similarity between 
the triplicates of each condition and the differences between the two conditions 







Figure 35: Generation of CRISPR/Cas9 mediated stable knockout of EZH2 in 
NKC cells. 
(A) Schematic displaying the isolation of primary PDAC cells (NKC cells) from 
caNfatc1;KrasG12D mice and further generation of CRISPR/Cas9 mediated stable 
knockdown of Ezh2 in these cells. (B) Nucleotide alignment confirming CRISPR/Cas9-
mediated knockout of Ezh2 in NKC cells. The position where the guide RNA interferes 
is highlighted in green. Red: sequence of CRISPR/Cas9 control cells; blue: sequence 
of CRISPR/Cas9 Ezh2 cells. (C) Western blot analysis in indicated cells confirming 
absence of Ezh2 expression in NKC cells upon CRISPR/Cas9 mediated Ezh2 
knockout. Actin is used as the house keeping gene. (D) PCA plot from RNA-seq 
analysis in CRISPR/Cas9 control and CRISPR/Cas9 Ezh2 NKC cells showing the 
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